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Summary 
1 
Summary 
The delivery of molecules into cells poses a major problem that has to be solved for the development of 
therapeutic agents acting on intracellular targets. Cargos which cannot penetrate cellular membranes by 
themselves due to their biophysical properties can achieve cell membrane permeability by fusion to 
protein transduction domains (PTDs). Since the design and generation of PTD-fused proteins can result 
in reduced expression and purification levels and/or in altered biophysical properties of cargos, two 
transporter systems for the transmembrane delivery of non-modified and modified cargos were 
developed. 
The first model system aimed at the internalization of a protein binder which can bind to, and 
subsequently sequester, an intracellular target molecule. Streptavidin (SA) was employed as a model 
protein binder and was internalized into mammalian cells via its ligand Strep-tag II, fused to a PTD. 
Inside the cells, the non-covalently bound PTD-Strep-tag II was displaced by biotin which exhibits a 
higher affinity to the SA binding pocket than Strep-tag II. Successful displacement of PTD-Strep-tag II 
was monitored by measuring the thermal tetramer stability of SA which is increased upon biotin binding. 
These results indicate that it is principally possible to intracellularly sequester target molecules with 
higher affinities for a protein binder than the PTD-ligand utilized for its internalization. Under therapeutic 
aspects, it could be envisioned to use such systems for the intracellular sequestration, and 
consequently, functional inactivation of pathologically relevant factors.  
A second transmembrane delivery system was developed for introducing cargos which themselves 
exert intrinsic biochemical activities, rather than acting as “passive” protein binders. Since covalent PTD 
fusion can influence cargo function, care was taken to introduce the cargos by non-covalent linkage to a 
transporter. PTD-fused SA and Strep-Tactin (ST) derivatives, termed Transvidins and Transtactins, 
were engineered as model transporters for biotin- and/or Strep-tag II-linked compounds. The expression 
of both transporters as insoluble inclusion bodies in bacteria prevented the common problems of both 
reduced expression levels and purification yields which have been observed for other PTD-fused 
proteins. Biochemical characterization of Transvidin and Transtactin variants bearing different PTDs 
revealed high thermal stabilities and robust secondary structures, indicating that SA and ST were 
extremely rigid protein scaffolds. Internalization studies demonstrated that both transporters facilitated 
simple, safe, and efficient transport of biotinylated and Strep-tag II-linked organics, peptides, proteins, 
and multicomponent complexes into cultured human cells. Transvidin- and Transtactin-introduced 
cargos were functionally active, as shown for the model protein horseradish peroxidase. These results 
demonstrate that Transvidin and Transtactin transporters provide universal and efficient delivery 
systems for biotinylated and Strep-tag II-fused cargos. 
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Zusammenfassung 
Der Transport von Molekülen durch die Zellmembran stellt für die Entwicklung von intrazellulär aktiven 
Therapeutika eine große technische Herausforderung dar. Moleküle, z. B. Proteine, die aufgrund ihrer 
biophysikalischen Eigenschaften per se nicht in der Lage sind die Zellmembran zu durchdringen, 
können diese Fähigkeit durch ihre Kopplung an Proteintransduktionsdomänen (PTDs) erlangen. Die 
Fusion von PTDs kann jedoch zu reduzierten Ausbeuten während der Produktion und Reinigung, sowie 
zu veränderten biophysikalischen Eigenschaften von Proteinen führen. Daher wurden zwei neue 
Transportersysteme entwickelt, um nicht-modifizierte sowie modifizierte Moleküle durch die 
Zellmembran zu schleusen.  
Das erste Modellsystem wurde generiert, um Bindungsproteine einzuschleusen, die intrazelluläre 
Zielmoleküle spezifisch sequestrieren können. Als Modell für ein solches Bindungsprotein diente 
Streptavidin (SA), das mit Hilfe einer an den SA-Bindungsliganden Strep-tag II gekoppelten PTD in 
Säugerzellen eingeschleust wurde. Im Zytoplasma wurde der PTD-Strep-tag II-Ligand durch Biotin 
ersetzt, das im Vergleich zu Strep-tag II eine höhere Affinität für die SA-Bindetasche besitzt. Der 
erfolgreiche Austausch von PTD-Strep-tag II durch Biotin wurde durch Bestimmung der thermischen 
Tetramerstabilität von SA nachgewiesen, die nach Bindung von Biotin ansteigt. Diese Ergebnisse 
zeigen, dass es prinzipiell möglich ist, intrazelluläre Moleküle spezifisch zu sequestrieren, die eine 
höhere Affinität zum Bindungsprotein aufweisen als der für die Internalisierung benutzte Ligand. Unter 
therapeutischen Gesichtspunkten ist es vorstellbar, entsprechende Systeme für die intrazelluläre 
Sequestrierung und funktionelle Inaktivierung pathologisch relevanter Faktoren einzusetzen. 
Ein zweites Transportsystem wurde entwickelt, um Moleküle in Zellen einzuschleusen, die im 
Gegensatz zu den eher „passiv“ wirksamen Bindungsproteinen eigene biochemische Aktivitäten 
aufweisen. Da eine kovalente Fusion von PTDs die funktionellen Eigenschaften von Molekülen 
beeinflussen kann, wurde ein besonderes Augenmerk darauf gelegt, Moleküle durch nicht-kovalente 
Kopplung an einen Transporter einzuschleusen. Hierfür wurden PTD-fusionierte SA- und Strep-Tactin-
(ST-) Derivate, sog. „Transvidine“ und „Transtactine“, als Transporter für Biotin- und/oder Strep-tag II-
gekoppelte Moleküle entwickelt. Durch Produktion der Transvidine und Transtactine als unlösliche 
bakterielle Einschlusskörper konnte das Problem der geringen Ausbeute während der Produktion und 
Reinigung umgangen werden, das für andere PTD-gekoppelte Proteine beobachtet wurde. Die 
biophysikalische Charakterisierung der Transvidin- und Transtactin-Transporter ergab hohe thermische 
Stabilitäten und stabile Sekundärstrukturen. Dies zeigte, dass sowohl SA als auch ST überaus rigide 
Proteingerüste darstellen. Zellkulturstudien zeigten, dass beide Transportersysteme Biotin- und/oder 
Strep-tag II-gekoppelte niedermolekulare Moleküle, Peptide, Proteine sowie multifaktorielle Komplexe 
einfach, sicher und effizient in humane Zellen internalisierten. Anhand des Modellproteins 
Meerrettichperoxidase wurde außerdem demonstriert, dass Proteine durch Transvidine und 
Transtactine in funktionell aktiver Form eingeschleust werden können. Diese Ergebnisse zeigen, dass 
Transvidine und Transtactine als universelle und effiziente Transportersysteme für die Internalisierung 
von Biotin- und Strep-tag II-gekoppelten Molekülen in Säugerzellen dienen können. 
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Chapter 1: Introduction 
1.1 TARGETED THERAPY 
One of the major objectives of molecular medicine is to understand the molecular basis of diseases and 
to translate this knowledge into novel therapeutic strategies. In principle, this can be achieved by a two-
step scenario: (i) the determination of genetic or biochemical alterations which are responsible for a 
given disease and (ii) the development of molecular tools that specifically correct these alterations 
(“targeted therapy”). 
 
TARGETS OF THERAPEUTIC AGENTS 
Different strategies for specifically interfering with the activity of genes and their products are feasible 
(figure 1-1). For instance, nucleic acids can be targeted on the DNA level by oligonucleotide-directed 
mutagenesis (IGOUCHEVA et al., 2004) and on the RNA level by antisense molecules (CROOKE, 
2004), ribozymes (BAGHERI and KASHANI-SABET, 2004), or RNA interference (RNAi) (FUCHS et al., 
2004). Intracellular and extracellular proteins (e.g. transcription factors and cell-surface receptors) can 
be targeted by organics, peptides, and protein binders, like antibodies (GRONER et al., 2004) and their 
fragments (HOLLIGER and HUDSON, 2005), or non-antibody-derived protein binders (BINZ et al., 
2005). Examples of non-antibody-derived protein binders are peptide aptamers, based on thioredoxin 
(LAVALLIE et al., 1993; HOPPE-SEYLER et al., 2004), or anticalins, based on the lipocalin-fold 
(SCHLEHUBER and SKERRA, 2005; SKERRA, 2007; SKERRA, 2008). 
 
In the case of cancer, the underlying pathogenesis can often be traced back to mutations in the 
genome. Transcription and translation finally lead to proteins with impaired functions or to altered 
protein levels (POIRIER, 2004). Inactivating mutations of tumor suppressor genes, like p53 (WHIBLEY 
et al., 2009), and activating mutations of proto-oncogenes, like Ras (DOWNWARD, 2003), play a major 
role for tumor development. In many cases, unaltered tumor suppressor proteins have an inhibitory 
effect on cell growth or promote apoptosis, whereas unaltered proto-oncoproteins stimulate cell growth 
and inhibit apoptosis. Consequently, the inactivation of tumor-suppressor genes and/or aberrant 
activation of proto-oncogenes can finally result in uncontrolled cell growth, as a hallmark of tumor cells 
(HANAHAN and WEINBERG, 2000). Conceivably, the correction of these defects may be of therapeutic 
value and diverse strategies have been developed to counteract the intracellular dysfunctions of these 
gene products, as delineated for the following examples. 
 
The p53 tumor suppressor gene is the most frequently mutated gene in human cancers and loss of 
normal p53 protein function is associated with cell cycle deregulation and resistance to apoptosis. Most 
of the p53 mutations are missense point mutations that accumulate in the DNA-binding core domain, 
thereby resulting in the disruption of DNA binding and loss of transcriptional transactivation of p53 target 
genes. Notably, mutant p53 core domain misfolding is reversible. For instance, a synthetic peptide 
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derived from the p53 C-terminal domain restored the specific DNA binding function of mutant p53 
proteins, resulting in growth inhibition and apoptotic tumor cell death (SELIVANOVA and WIMAN, 
2007). Moreover, the transcriptional transactivation function of mutant p53 was also restored by 
intracellularly expressed single chain (sc) Fv fragments derived from anti-p53 monoclonal antibodies 
(CARON DE FROMENTEL et al., 1999). 
 
 
Figure 1-1. Different strategies for interfering with the activity of genes and proteins: Nucleic acids can 
be specifically targeted on the DNA level by site-directed mutagenesis and on the RNA level by antisense 
molecules, ribozymes, or RNA interference. Intracellular and extracellular proteins can be targeted by 
organics, peptides, and protein binders. 
Activating mutations of the growth-promoting cellular RAS genes are found in approximately 20 % of all 
human cancers and can reach high frequencies for particular tumor types, being detectable, for 
example, in approximately 90 % of pancreatic and 50 % of colorectal cancers (DOWNWARD, 2003). 
Therapeutic agents that can interfere with aberrant RAS signalling are therefore considered to bear 
great potential for the development of novel cancer treatments (DOWNWARD, 2003). Several agents 
which target RAS at the protein level have been developed, including peptide aptamers that can 
specifically inhibit oncogenic RAS proteins as opposed to wildtype RAS (XU and LUO, 2002). 
 
Oncogenes involved in human carcinogenesis can also be of viral origin. For example, specific types of 
human papillomaviruses (HPVs), including the high-risk types HPV-16 and HPV-18, cause cervical 
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cancer. The anti-apoptotic HPV E6 oncoprotein plays a crucial role for maintenance of the malignant 
phenotype of HPV-positive cancer cells (ZUR HAUSEN, 2002). Since E6, as a viral oncoprotein, is not 
expressed in healthy cells, E6 inhibitors should allow a selective attack on HPV-positive cells. As proof 
of concept, intracellularly expressed peptides (DYMALLA et al., 2008) and protein binders (BUTZ et al., 
2000; GRIFFIN et al., 2006; LAGRANGE et al., 2007), which specifically bind to E6, induced apoptosis 
in HPV-positive cancer cells. 
 
Thus, the reactivation of tumor suppressors and/or inactivation of cellular or viral oncoproteins by 
intracellularly expressed therapeutic peptides and protein binders should bear remarkable potential for 
targeted cancer therapy. This could be achieved by the intracellular expression of such inhibitors from 
therapeutic genes. Yet, the internalization of genetic material into eukaryotic cells either using viral 
vectors or by non-viral mechanisms, such as membrane permeabilization, microinjection, or 
electroporation, remains problematic: Firstly, viral vectors often suffer from significant problems such as 
immunogenicity, lack of specificity of transgene delivery, and/or insertional mutagenesis (THOMAS et 
al., 2003). Secondly, membrane permeabilization can only be efficiently used in ex vivo cellular assays 
(NITIN et al., 2004). Thirdly, microinjection and electroporation are invasive and may cause severe 
damage to cells (NITIN et al., 2004). Therefore, many efforts are currently undertaken to develop 
methods which enable the transmembrane delivery of therapeutic peptides and proteins. 
 
1.2 TRANSMEMBRANE DELIVERY OF THERAPEUTIC AGENTS 
Most of the therapeutic agents prescribed today belong to the group of cell-permeable small molecules 
which are derived from organics and peptides. In general, small molecules enter the cell by free 
diffusion (figure 1-2) and interact with intracellular targets in defined ways, for instance by blocking the 
target’s active site with sufficient affinity or by irreversible covalent binding. However, many small 
molecules suffer from lack of specificity, leading to unwanted side effects and toxicity. Macromolecular 
therapeutic agents based on nucleic acids, peptides, or proteins have several hypothetical advantages 
over organics (LEADER et al., 2008). Firstly, they possess a highly specific and complex set of 
functions that cannot be mimicked by small molecules. Secondly, since nucleic acids, peptides, and 
proteins target molecules in a highly specific way, they often have less potential to induce unspecific 
side effects than small molecules which can bind to similarly shaped pockets of proteins other than the 
target. Thirdly, protein therapeutics can provide effective replacement treatment for diseases in which 
proteins are mutated, truncated, or not expressed. 
 
On the other hand, most of the macromolecular therapeutic agents cannot penetrate cellular 
membranes of intact cells due to their biophysical properties, like size, charge, and polarity. This is 
especially true for nucleic-acid-based therapeutics or for peptides and protein binders (e.g. peptide 
aptamers). Nevertheless, due to their potential advantages in comparison to small molecules, there has 
been growing interest in the use of therapeutic macromolecular agents against intracellular targets. The 
Chapter 1 
 
16 
transmembrane delivery of such molecules into cells is still a major technical obstacle. In the following, 
two possible strategies to make therapeutic agents cell-permeable are described in-depth. 
 
RECEPTOR-MEDIATED ENDOCYTOSIS 
One way to achieve target cell-specific internalization is the fusion of therapeutic agents to ligands of 
cell-surface receptors. Following receptor-ligand interaction, the ligand-fused therapeutic agent is taken 
up into endosomal compartments by receptor-mediated endocytosis (figure 1-2) (WILEMAN et al., 1985; 
ALLEN, 2002; QIAN et al., 2002). After endosomal escape, the therapeutic agent can, for instance, 
inhibit a given oncoprotein by occupying its active site. However, this method requires the covalent 
coupling of a ligand to the cargo which often leads to altered properties with respect to ligand affinity as 
well as to the activity of the cargo. Moreover, this approach is highly restricted to specific cell types that 
express a certain cell-surface receptor and to the internalization properties of the targeted receptor. An 
alternative way to induce cell-membrane permeability of cargos is their linkage to peptide and protein 
transduction domains (PTDs). 
 
PROTEIN TRANSDUCTION DOMAINS 
PTDs, also known as cell penetrating peptides (CPPs) or membrane permeable peptides (MPPs), are 
short, in general 5 to 20 amino acids long peptides, comprising amino acid sequences which enable 
their own internalization into a variety of mammalian and human cell types (table 1-1, figure 1-2) (DIETZ 
and BAHR, 2004). PTDs can be classified into cationic and non-cationic peptides. Examples of well-
studied cationic PTDs are the Tat13 peptide of the HIV-1 trans-activator protein (FRANKEL and PABO, 
1988; GREEN and LOEWENSTEIN, 1988; FAWELL et al., 1994; VIVES et al., 1997; HONDA et al., 
2005), penetratin, also known as Ant16 (DEROSSI et al., 1994; HONDA et al., 2005), and Ant7 
(FISCHER et al., 2001; HONDA et al., 2005), the two latter derived from the homeodomain of the 
Drosophila melanogaster Antennapedia protein, or polyarginines like R9 (MITCHELL et al., 2000; 
FUTAKI et al., 2001; HONDA et al., 2005). TLM12, derived from the pre-S domain of HBV, is an 
example of a non-cationic PTD forming an -helix with an amphipathic structure (OESS and HILDT, 
2000; STOECKL et al., 2006).  
 
PTD Sequence 
Tat13 YGRKKRRQRRRPP 
Ant16 RQIKIWFQNRRMKWKK 
Ant7 RRMKWKK 
R13 RRRRRRRRRRRRR 
R9 RRRRRRRRR 
TLM12 PLSSIFSRIGDP 
Table 1-1. Protein transduction domains: Amino acid sequences of cationic and non-cationic PTDs. 
The precise uptake mechanism of PTDs is currently a topic of lively discussion. However, in the case of 
cationic PTDs, it is most likely that the positively charged side chains of the PTDs interact with the 
anionic structure at the cell surface leading to an increased local concentration of PTDs, subsequently 
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allowing cellular entry by a fluid-phase endocytotic mechanism (figure 1-2) (RICHARD et al., 2003; 
BROOKS et al., 2005; GUMP and DOWDY, 2007). It is remarkable that molecules that are bound to 
PTDs can be internalized concomitantly (GROS et al., 2006). The uptake of non-cationic PTDs is also 
receptor-independent but, apart from that, their internalization mechanisms are still largely unclear. 
 
 
Figure 1-2. Ways through the cell membrane: Cell-permeable organics can enter the cell by free diffusion. 
Ligand-fused macromolecular therapeutic agents can be internalized by receptor-mediated endocytosis. 
PTDs can induce their own internalization via receptor-independent endocytosis, thereby mediating the 
internalization of bound non-cell-permeable cargos. 
Since their discovery in 1988 (FRANKEL and PABO, 1988; GREEN and LOEWENSTEIN, 1988), a 
broad variety of bioactive molecules, ranging from nucleic acids, peptides, proteins, and even liposomes 
and particles, has been delivered by PTDs into cells both in vitro and in vivo (DIETZ and BAHR, 2004). 
This technology is thus considered to bear enormous potential to introduce macromolecular 
therapeutics into living cells (TREHIN and MERKLE, 2004; GUMP and DOWDY, 2007). Notably, there 
are reports indicating that PTDs can also penetrate intact epidermis and dermis which may enable the 
transdermal delivery of cargos upon topical application (ROTHBARD et al., 2000; JIN et al., 2001; 
PARK et al., 2002). 
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One drawback of this technology is the genetic fusion of PTDs to cargos that can result in reduced 
protein expression and purification levels (HONDA et al., 2005). Furthermore, the genetic or chemical 
linkage of PTDs can have an impaired effect on the biophysical properties of the cargo (HONDA et al., 
2005). 
 
1.3 UNIVERSAL TRANSMEMBRANE DELIVERY SYSTEMS 
In view of these obstacles, attempts have been made to generate transmembrane delivery systems that 
allow the concomitant internalization of non-covalently bound cargos. As further outlined below, these 
delivery systems often use the unrivalled high affinity of streptavidin (SA) to its natural ligand biotin as a 
basis for linking the therapeutic effect of a drug to the internalization property of a PTD. 
 
THE SA/BIOTIN SYSTEM 
SA is an extracellular homotetrameric protein secreted by the bacterium Streptomyces avidinii (TAUSIG 
and WOLF, 1964). Its name is derived from its bacterial source and from its structurally (LIVNAH et al., 
1993) and functionally (CHAIET and WOLF, 1964) analogous protein avidin (GREEN, 1975). SA was 
discovered in the early 1960s when the fermentation filtrates of Streptomycetes were searched for 
antibiotic activity (CHAIET et al., 1963). This antibiotic activity is related to its ability to strongly bind the 
small growth factor biotin with an affinity constant (KA) of 2.5 . 1013 M-1 which is among the strongest 
non-covalent bonds known in nature. Cloning and sequencing of the SA gene of Streptomyces avidinii 
(ARGARANA et al., 1986) showed that the gene coded for a 183 amino acid long protein. The first 24 
amino acids comprise a signal sequence for secretion. After secretion, the matured SA monomer 
subunit is composed of 159 amino acids with a MW of 16.5 kDa, which is subsequently cleaved both at 
the N- and C-terminus by extracellular proteases (BAYER et al., 1989). The resulting core SA monomer 
consists of 125 to 127 amino acids (MW = 13.2 kDa) and can be expressed as cytosolic inclusion 
bodies in Escherichia coli (E. coli) (SANO and CANTOR, 1990; THOMPSON and WEBER, 1993). Core 
SA is stable against further proteolytic degradation and retains its full biotin-binding activity. The crystal 
structure of core SA was resolved in the late 1980s (PAHLER et al., 1987). Each subunit consists of 
eight antiparallel -strands, which fold to an up-and-down -barrel (figure 1-3). Subunit pairs of SA are 
hydrogen-bonded to each other forming a symmetric dimer with a pair of dimers interfacing each other 
and thus constituting the naturally occurring tetrameric structure. Each subunit possesses one exposed 
biotin-binding pocket. Therefore, the SA tetramer can bind up to four biotin molecules. Apart from its 
exceptional ligand-binding properties, SA bears unusual high stability against heat (GONZALEZ et al., 
1999), denaturants, extreme pH, and against the activity of proteolytic enzymes (LAITINEN et al., 2006). 
Due to these unexampled characteristics, SA is widely utilized for different disciplines of biosciences 
and biomedicine. 
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BIOTIN 
Biotin, also known as vitamin B7, vitamin H, or coenzyme R (MW = 244 Da), was first discovered as a 
growth factor in 1901. It consists of two fused rings and an aliphatic valeric acid side chain with a 
carboxyl group in the end (figure 1-3). The natural function of biotin is to carry carboxyl groups and  
 
  
SA and biotin (green), PDB entry 1STP 
(WEBER et al., 1989) 
SA and Strep-tag II (green), PDB entry 1RSU 
(SCHMIDT et al., 1996) 
Figure 1-3. Crystal structures of monomeric SA with biotin and Strep-tag II. 
to function as a cofactor for carboxylation reactions catalyzed by biotin-dependent carboxylases. Most 
prokaryotes and plants are able to synthesize biotin by themselves, whereas animals and humans need 
biotin in their diet. Various biotin derivatives were designed for biotechnological applications. They 
include 2-iminobiotin (HOFMANN et al., 1980) and desthiobiotin (GREEN, 1975; VOSS and SKERRA, 
1997), which show reversible binding and therefore are used for purification processes. 
 
SA-BINDING PEPTIDES 
In addition to biotin and its derivatives, various peptide motifs were designed which can occupy the 
biotin-binding pocket reversibly (table 1-2). The Strep-tag represents a nine amino acid peptide that  
 
SA-binding peptides Sequence 
Strep-tag AWRHPQFGG 
Strep-tag II WSHPQFEK 
Nano-tag9 DVEAWLGAR 
Nano-tag15 DVEAWLGARVPLVET 
SBP MDEKTTGWRGGHVVEGLAGELEQLRARLEHHPQGQREP 
Table 1-2. SA-binding peptides: Amino acid sequences of SA-binding peptide motifs. 
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requires the peptide carboxylate group of C-terminal glycine to form a salt bridge with the guanidinium 
group of R84 of wildtype SA and therefore can only be fused to the C-terminus of recombinant proteins 
(SCHMIDT and SKERRA, 1993; SCHMIDT et al., 1996). To overcome this limitation, a terminus-
independent Strep-tag II peptide was generated (VOSS and SKERRA, 1997; SKERRA and SCHMIDT, 
1999; KORNDORFER and SKERRA, 2002; SCHMIDT and SKERRA, 2007). The coding sequence of 
the Strep-tag II peptide can be easily fused to recombinant proteins during DNA subcloning. Moreover, 
Strep-tag II is biologically inert, proteolytically stable, and does usually not interfere with membrane 
translocation or protein function (SCHMIDT and SKERRA, 2007). Further examples of SA-binding 
peptides are Nano-tag9 (LAMLA and ERDMANN, 2004), Nano-tag15 (LAMLA and ERDMANN, 2004), 
and the SBP-tag (KEEFE et al., 2001), which all bind to SA with a nanomolar affinity. Strep-tag II bears 
a lower affinity to SA (KD = 72 µM) than the previous Strep-tag (KD = 37 µM). Therefore, Strep-Tactin 
(ST), as an SA-derivative with amino acid substitutions E44I, S45G, and V47R (numbering according to 
wildtype SA) was developed (VOSS and SKERRA, 1997). Recombinant proteins carrying an N- or C-
terminal Strep-tag II (KD = 1 µM) can be directly purified from the host cell extract by affinity 
chromatography on immobilized ST. 
 
STREPTAVIDIN-BASED UNIVERSAL TRANSMEMBRANE DELIVERY SYSTEMS USING RECEPTOR-
TARGETING 
Various agents have been delivered into cells by receptor-mediated endocytosis using SA-based 
transporter systems. For instance, biotinylated cargos have been internalized into mammalian cells by 
using SA and biotinylated RNA aptamers which bind to specific surface receptors (CHU et al., 2006) or 
by chimeric SA transporters with an N-terminally fused peptide targeting a receptor expressed on 
cancer cells (MASUDA et al., 2006). 
 
STREPTAVIDIN-BASED UNIVERSAL TRANSMEMBRANE DELIVERY SYSTEMS USING PROTEIN 
TRANSDUCTION DOMAINS 
As an alternative to receptor-targeting, attempts have been made to generate universal cell permeable 
transporters based on SA that allow the concomitant internalization of cargos by non-covalent binding of 
biotin-fused cargos. For instance, Nitin et al. used SA to bridge the internalization properties of a 
biotinylated PTD to a biotinylated molecular beacon as an example for a nucleic-acid-based diagnostic 
agent (NITIN et al., 2004). In a similar setting, biotinylated siRNA molecules were internalized by using 
SA and biotinylated PTDs (WANG et al., 2007). Furthermore, model cargos (e.g. -galactosidase) fused 
to SA as scaffolds were delivered into cells by PTD-biotin (MAI et al., 2002). Vice versa, SA fused to the 
Tat11 PTD (YGRKKRRQRRR) was generated as a cell-permeable transporter (Tat11-SA) for 
biotinylated proteins (figure 1-4) (ALBARRAN et al., 2005; RINNE et al., 2007).  
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Figure 1-4. Model of Tat11-SA: Tat11 
peptides are shown in black, SA monomers in 
light and dark gray. Biotin is shown in black 
spheres. Adopted from (ALBARRAN et al., 
2005). 
 
However, biotinylation requires chemical linkage and may be inefficient for some cargos leading to the 
biotinylation of only a small portion of the cargo. Furthermore, it cannot be excluded that biotinylation of 
a cargo or its fusion to a scaffold, like SA, may impair its activity. To overcome possible difficulties due 
to chemical modifications of the cargo, Futaki et al. synthesized a cell-permeable nickel-nitrilotriacetic 
acid (R8-Ni-NTA) for polyhistidine tagged recombinant proteins (FUTAKI et al., 2004). Moreover, Mie et 
al. developed a system where the cargo is captured by an antibody and internalized due to the 
interaction with PTD-fused protein A that interacts with the Fc portion (MIE et al., 2003; MIE et al., 
2006). However, this system consists of several components and requires an antibody that recognizes 
the target with high affinity and at the same time does not change the target’s activity. 
 
1.4 RESEARCH OBJECTIVES 
INTERNALIZATION OF NON-MODIFIED PROTEIN SCAFFOLDS BY PTD-FUSED LIGANDS 
The first goal of this thesis was the development of a novel and biologically safe two-component 
delivery system for the internalization of a non-modified protein binder. The system consists of (i) a non-
cell permeable protein binder containing a binding pocket for an intracellular target molecule and (ii) a 
ligand which interacts with the same pocket more weakly and is fused to a PTD. Binding of the PTD-
ligand to the protein binder should allow subsequent internalization of the complex. At the intracellular 
level, the ligand should then be displaced by the intracellular target which exhibits a higher binding 
affinity to the pocket. In principle, such a system could allow the intracellular sequestration and, 
consequently, functional inactivation of the target molecule. The system should be developed and 
tested by introducing SA via PTD-Strep-tag II. Subsequently, PTD-Strep-tag II should be replaced by 
biotin which binds to the same SA pocket with higher affinity. 
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DEVELOPMENT OF CELL-PERMEABLE TRANSMEMBRANE TRANSPORTERS FOR BIOTIN- AND  
STREP-TAG II-FUSED CARGOS 
The design and generation of PTD-fused cargos (e.g. PTD-fused therapeutic agents) can result in 
reduced expression and purification levels and in altered biophysical properties of the cargos (HONDA 
et al., 2005). Therefore, as a second goal, a universal transmembrane delivery system should be 
developed which circumvents covalent PTD fusion to the cargo. Mechanistically, the system takes 
advantage of the interaction of SA and ST proteins with biotin and SA-binding peptides, like Strep-tag II. 
Specifically, PTD-fused SA and ST molecules should be tested for their potential to internalize biotin- or 
Strep-tag II-fused molecules into human cells. The intracellular distribution of the transporter and the 
cargo should be analyzed and the functionality of an introduced model enzyme tested. In principle, this 
system could allow the cellular internalization of any biotin- or Strep-tag II-linked compound. 
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Chapter 2: Results 
For the implementation of the projects, a series of model cargos and transporters were produced, 
namely SA and ST, which served as cargos to be internalized by PTD-fused biotin and Strep-tag II. In 
addition, (i) SA, fused to various PTDs, termed Transvidins (from transduction and streptavidin), and  
(ii) ST, fused to various PTDs, termed Transtactins (from transduction and Strep-Tactin) had to be 
constructed, produced, and characterized. The ultimate aim for these latter molecules was to evolve 
them into universal transporters for biotinylated and/or Strep-tag II-fused cargos. 
 
2.1 CONSTRUCTION, EXPRESSION, AND PURIFICATION OF STREPTAVIDIN 
AND ITS DERIVATIVES 
CONSTRUCTION OF EXPRESSION VECTORS 
For large-scale production of core SA, the pSA1 expression vector (figure 2-1) was utilized (kindly 
provided by P. S. Stayton) which expresses the core SA gene from the pET21a vector backbone 
(CHILKOTI et al., 1995). 
 
                        
pSA1
5772 bp
lac I
bla (Ap) sequence
lac operator
SA
T7 promoter
ColE1 pBR322 origin
f1 origin
T7 terminator
NdeI (568)
HindIII (174)
    
 
Figure 2-1. Scheme of the vector pSA1 for large-scale expression of core SA: The expression vector 
contains a lac I gene which codes for the lac repressor protein, a T7 promoter which is specific to T7 RNA 
polymerase, a lac operator which blocks transcription, f1 and ColE1 origins of replication, and the bla ampicillin 
resistance gene. 
Vector pST1 for the large-scale expression of ST was generated from pSA1 by replacement of the 
triplets coding for E33, S34, and V36 (numbering according to core SA) using in vitro Quik-change side-
directed mutagenesis. The desired mutations were verified by DNA sequencing using T7 promoter and 
T7 terminator oligonucleotide primers. Sequences of SA and ST genes were aligned in figure 2-2, the 
mutated nucleotides converting SA to ST were highlighted in red. 
Chapter 2 
26 
     1       10        20        30        40        50        60 
     |        |         |         |         |         |         | 
pST1 ATGGCTGAAGCTGGTATCACCGGCACCTGGTACAACCAGCTGGGATCCACCTTCATCGTT 
pSA1 ATGGCTGAAGCTGGTATCACCGGCACCTGGTACAACCAGCTGGGATCCACCTTCATCGTT 
     ************************************************************ 
    61       70        80        90       100       110       120 
     |        |         |         |         |         |         | 
pST1 ACCGCTGGTGCTGACGGTGCTCTGACCGGTACCTACATCGGTGCGAGGGGTAACGCTGAA 
pSA1 ACCGCTGGTGCTGACGGTGCTCTGACCGGTACCTACGAATCCGCTGTTGGTAACGCTGAA 
     ************************************      **    ************ 
   121      130       140       150       160       170       180 
     |        |         |         |         |         |         | 
pST1 TCTAGATACGTTCTGACCGGTCGTTACGACTCCGCTCCGGCTACCGACGGTTCCGGAACC 
pSA1 TCTAGATACGTTCTGACCGGTCGTTACGACTCCGCTCCGGCTACCGACGGTTCCGGAACC 
     ************************************************************ 
   181      190       200       210       220       230       240 
     |        |         |         |         |         |         | 
pST1 GCTCTGGGTTGGACCGTTGCTTGGAAAAACAACTACCGTAACGCTCACTCCGCTACCACC 
pSA1 GCTCTGGGTTGGACCGTTGCTTGGAAAAACAACTACCGTAACGCTCACTCCGCTACCACC 
     ************************************************************ 
   241      250       260       270       280       290       300 
     |        |         |         |         |         |         | 
pST1 TGGTCTGGCCAGTACGTTGGTGGTGCTGAAGCTCGTATCAACACCCAGTGGTTGTTGACC 
pSA1 TGGTCTGGCCAGTACGTTGGTGGTGCTGAAGCTCGTATCAACACCCAGTGGTTGTTGACC 
     ************************************************************ 
   301      310       320       330       340       350       360 
     |        |         |         |         |         |         | 
pST1 TCCGGCACCACCGAAGCTAACGCGTGGAAATCCACCCTGGTTGGTCACGACACCTTCACC 
pSA1 TCCGGCACCACCGAAGCTAACGCGTGGAAATCCACCCTGGTTGGTCACGACACCTTCACC 
     ************************************************************ 
   361      370       380       390 
     |        |         |         | 
pST1 AAAGTTAAACCGTCCGCTGCTTCCTAATAA 
pSA1 AAAGTTAAACCGTCCGCTGCTTCCTAATAA 
     ****************************** 
 
Figure 2-2. Sequence alignment of the 387 bp long SA and ST genes: Start and stop codons are 
highlighted in blue. The mutated nucleotides for the amino acid substitutions E33I, S34G, and V36R are shown 
in red. 
Both SA and ST genes were translated in silico into their amino acid sequences and aligned to confirm 
the amino acid substitutions E33I, S34G, and V36R (figure 2-3). 
 
     1       10        20        30        40        50        60   65 
     |        |         |         |         |         |         |    | 
ST   MAEAGITGTWYNQLGSTFIVTAGADGALTGTYIGARGNAESRYVLTGRYDSAPATDGSGTALGWT 
SA   MAEAGITGTWYNQLGSTFIVTAGADGALTGTYESAVGNAESRYVLTGRYDSAPATDGSGTALGWT 
     ********************************  * ****************************** 
    66  70        80        90       100       110       120     128 
     |   |         |         |         |         |         |       | 
ST   VAWKNNYRNAHSATTWSGQYVGGAEARINTQWLLTSGTTEANAWKSTLVGHDTFTKVKPSAAS 
SA   VAWKNNYRNAHSATTWSGQYVGGAEARINTQWLLTSGTTEANAWKSTLVGHDTFTKVKPSAAS 
    *************************************************************** 
Figure 2-3. Alignment of the SA and ST amino acid sequences: The amino acid substitutions E33I, S34G, 
and V36R to convert SA into ST are highlighted in red. 
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For generating different Transvidin and Transtactin variants, the coding sequences for the cationic 
PTDs Ant16, Ant7, Tat13, R9, R13, and for the non-cationic PTD TLM12 were fused in frame to the 5’ 
end of the SA or ST genes and subcloned into pET-21a. A triplet encoding glycine was introduced 
between the coding sequences for the PTDs and the SA or ST genes to increase the flexibility of the  
 
             1 3                                                   4 6 
             | |                                                   | | 
      SA/ST  ATG---------------------------------------------------GCT 
ANT16-SA/ST  ATGCGCCAGATTAAGATTTGGTTCCAGAACCGCCGCATGAAGTGGAAGAAGGGTGCT 
 ANT7-SA/ST  ATGCGTC---------------------------GTATGAAGTGGAAGAAGGGTGCT 
  R13-SA/ST  ATGAGACGCAGAAGAC---------GCAGAAGACGCAGAAGAAGAAGAAGAGGTGCT 
   R9-SA/ST  ATGAGACGCAGAAGAA---------GAAGAAGACGCAGA------------GGTGCT 
TAT13-SA/ST  ATGTACGGAAGAAAGA---------AGCGCAGACAAAGAAGACGTCCACCAGGTGCT 
TLM12-SA/ST  ATGCCCTTATCGTCAAT------------CTTCTCGAGGATTGGGGACCCTGGTGCT 
             ***                                                   *** 
 
Figure 2-4. DNA sequence alignment of the different PTDs: PTDs, highlighted in blue, were fused in frame 
to the 5’ end of the SA and ST genes, shown in green. The triplet for glycine between the coding sequences 
of the PTDs and the SA/ST genes is shown in black. Numbering according to the SA gene. 
              1                 2      10        20 
              |                 |       |         | 
       SA/ST  M                 AEAGITGTWYNQLGSTFIV 
 ANT16-SA/ST  MRQIKIWFQNRRMKWKKGAEAGITGTWYNQLGSTFIV 
  ANT7-SA/ST  M---------RRMKWKKGAEAGITGTWYNQLGSTFIV 
   R13-SA/ST  M---RRRRRRRRRRRRRGAEAGITGTWYNQLGSTFIV 
    R9-SA/ST  M-------RRRRRRRRRGAEAGITGTWYNQLGSTFIV 
 TAT13-SA/ST  M---YGRKKRRQRRRPPGAEAGITGTWYNQLGSTFIV 
 TLM12-SA/ST  M    PLSSIFSRIGDPGAEAGITGTWYNQLGSTFIV 
              *                 ******************* 
 
Figure 2-5. Alignment of the amino acid sequences of the Transvidin and Transtactin proteins after in 
silico translation: The various PTDs are highlighted in blue, SA and ST in green. The glycine residue which 
was introduced to increase the flexibility of the PTDs is shown in black. Numbering according to SA. 
PTDs. All obtained expression vectors were verified by analytical restriction analysis (data not shown) 
and by DNA sequencing (figure 2-4). Figure 2-5 shows an alignment of the amino acid sequences of the 
PTD-fused SA and ST proteins after in silico translation. 
 
EXPRESSION 
E. coli-K12-strain BL21(DE3) was transformed for large-scale expression of SA, ST, Transvidin, and 
Transtractin proteins. Recombinant proteins were expressed overnight by IPTG-induction as cytosolic 
inclusion bodies. Coomassie-stained SDS-polyacrylamide gels of separated bacterial whole cell protein 
extracts sampled after 20 hours indicated that - apart from R13-SA/ST - all individual recombinant 
proteins were expressed in full length, exhibiting a migration behavior similar as expected for their 
calculated MWs (table 2-1, figure 2-6). The lack of R13-SA/ST expression may be related to the highly 
biased E. coli codon usage. In particular, the arginine AGA codon which was predominantly used for 
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primer design is extremely rare and the tRNA of this codon is poorly produced in E. coli (IKEMURA, 
1981; KOMINE et al., 1990). This may also explain the lower expression levels observed for 
recombinant R9-SA/ST proteins. 
 
Protein MW [Da]  [M-1cm-1] 
SA 13402.6 41940 
Ant16-SA 15688.4 52940 
Ant7-SA 14473.9 47440 
R13-SA 15490.1 41940 
R9-SA 14865.3 41940 
Tat13-SA 15195.7 43430 
TLM12-SA 14730.1 41940 
ST 13413.7 41940 
Ant16-ST 15699.4 52940 
Ant7-ST 14485.0 47440 
R13-ST 15501.1 41940 
R9-ST 14876.4 41940 
Tat13-ST 15206.8 43430 
TLM12-ST 14741.2 41940 
Table 2-1. Calculated MWs and extinction coefficients (s) of SA and its derivatives: MWs and s of all 
recombinant proteins were calculated according to their amino acid sequences. 
In the case of Ant16- and R13-fusion protein productions, the samples taken after an IPTG-induction of  
20 hours indicated the overexpression of an additional protein with an MW of approximately 22 kDa 
(figure 2-6). No further attempts were started to identify this protein. 
 
PURIFICATION 
Inclusion bodies containing individual Transvidins and Transtactins were harvested and denatured 
proteins were refolded and purified by fractionated ammonium sulfate precipitation, as previously 
published for SA (SCHMIDT and SKERRA, 1994). Ant16-SA and Ant16-ST could not be refolded  
(figure 2-7), most likely due to the N-terminal part of the Ant16 PTD, since Ant7-SA and Ant7-ST 
inclusion bodies could be refolded without any problem. The yields of purified PTD-SA/ST proteins 
depended on the expression level as well as on the refolding process and ranged from 10 mg to 80 mg 
per 1 L expression volume. Purified SA showed a protein yield of approximately 30 mg/L. 
 
2.2 BIOPHYSICAL CHARACTERIZATION OF STREPTAVIDIN AND ITS 
DERIVATIVES 
After purification, all recombinant proteins were characterized by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE), matrix-assisted-laser desorption/ionization time-of-flight mass  
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Figure 2-6. Expression of PTD-
SA/ST proteins: Coomassie-
stained SDS-polyacrylamide gels 
of separated bacterial extracts 
sampled before IPTG-induction  
(0 h), or after 1, 2, and 20 hours 
following IPTG treatment. 
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Figure 2-7. Coomassie-stained SDS-
polyacrylamide gel analyzing Ant16-SA/ST 
refolding: The pelleted fractions after refolding 
attempts indicated that Ant16-SA and Ant16-ST 
proteins remained denatured. 
 
 
spectrometry (MALDI-TOF MS), Edman sequencing, far-UV circular dichroism (CD) spectroscopy, and 
thermal (tetramer) stability analysis. 
 
SDS-PAGE ANALYSES 
SDS-PAGE analyses were performed to estimate MWs and purities of SA, ST, and their PTD-linked 
derivatives (figure 2-8). 
 
 
Figure 2-8. Coomassie-stained SDS-polyacrylamide gels of purified proteins. 
Purified proteins exhibited a migration behavior similar to their expected theoretical masses (table 2-1) 
and showed more than 95 % in purity as estimated by Coomassie-staining (figure 2-8). 
 
MASS SPECTROMETRY 
MALDI-TOF MS analyses of desalted protein samples were performed to determine their mass-to-
charge (m/z, MH+) values. Figure 2-9 exemplarily shows the result for Ant7-ST. 
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Figure 2-9. MALDI-TOF MS analyses: Purified Ant7-ST protein showed an observed MH+ value (right peak) 
similar to its calculated average MH+(av) value.  
The observed MH+ values of Tat13-SA/ST, Ant7-SA/ST, and R9-SA/ST were similar to their average 
theoretical (MH+(av)) values with discrepancies of less than 5 Da (table 2-2). Differences between the 
observed and theoretical values of SA/ST and TLM12-SA/ST could be explained by removal of the N-
terminal methionines due to the activity of the E. coli methionine aminopeptidase which removes the 
start-methionine, depending on the side chain length of the second amino acid (MOGK et al., 2007). 
 
EDMAN SEQUENCING 
N-terminal methionine removal from SA/ST and TLM12-SA/ST was confirmed by Edman sequencing. 
All cationic PTDs retained the start methionine (table 2-2). 
 
Protein MALDI-TOF MS Start- 
 Theoretical 
MH+(av) 
Observed 
MH+ 
Difference 
MH+(av) – MH+ 
methionine 
SA 13403.7 13273.8 129.9 - 
TAT13-SA 15196.9 15196.5 0.4 + 
ANT7-SA 14475.1 14474.5 0.6 + 
R9-SA 14866.5 ND ND + 
TLM12-SA 14731.2 14598.4 132.8 - 
ST 13414.8 13287.5 127.3 - 
TAT13-ST 15207.9 15205.1 2.8 + 
ANT7-ST 14486.2 14485.4 0.8 + 
R9-ST 14877.5 14882.4 -4.9 + 
TLM12-ST 14742.3 14613.0 129.3 -  
Table 2-2. MALDI-TOF MS and Edman sequencing: MALDI-TOF MS and Edman sequencing of selected 
proteins confirmed that unfused SA/ST and TLM12-SA/ST proteins lacked the N-terminal start-methionine. 
Start-methionine present (+), absent (-). ND: not determined. 
MH+ MH2+ 
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THERMAL TETRAMER STABILITY 
SA and ST tetramerization (VOSS and SKERRA, 1997) is essential for forming the binding pocket for 
biotin and Strep-tag II which lies at the interface between SA and ST subunits, respectively (SANO and 
CANTOR, 1995). SA and ST tetramers are extremely stable even in the presence of SDS and therefore 
can be detected on SDS-polyacrylamide gels (BAYER et al., 1996; WANER et al., 2004; HUMBERT et 
al., 2005). Temperature dependence of tetramer breakup was studied by heating and subsequent SDS-
PAGE analyses, as exemplified for Tat13-SA either analyzed alone, or in complex with biotin, Strep-tag, 
or Strep-tag II (figure 2-10). Temperature-dependent tetramer stabilities of all recombinant proteins were 
compiled in figure 2-11. Up to a temperature of 65 °C, SA proteins were detectable exclusively in a 
tetrameric state. Notably, all PTD fusions increased the tetramer stability of SA up to 70 °C. SA and all 
those Transvidins complexed with biotin showed increased tetramer stabilities up to 90 °C. Strep-tag 
and Strep-tag II peptides induced no changes in the temperature-dependent tetramer breakup of SA 
compared to the ligand-free protein preparations. The amino acid substitutions which were required to 
convert SA into ST decreased the tetramer stability by 5 °C. The Tat13-ST and R9-ST Transtactins 
showed similar stabilities compared to the Transvidin proteins. Ant7-ST and TLM12-ST tetramers were 
stable up to 65 °C. All pre-incubations of unfused ST or individual Transtactins with biotin, Strep-tag, 
and Strep-tag II, respectively, had no effect on temperature-dependent ST tetramer breakup. Summed 
up, these data indicated that all investigated transporters were stable over a wide range of temperatures 
with regard to their tetramer forming capacity. 
 
CIRCULAR DICHROISM SPECTROSCOPY 
Since PTD fusions can influence the biophysical properties of cargos (HONDA et al., 2005), CD 
spectroscopy was performed to assess possible alterations in the secondary structures of SA and ST 
proteins caused by their N-terminal PTD-fusions. Protein preparations, dialyzed against H2O, were 
analyzed by far-UV CD spectroscopy from 190 nm to 240 nm. The spectra of all SA derivatives showed 
almost identical curve progressions, similar to the CD spectrum of core SA (figure 2-12). CD spectra 
were interpreted using PEPFIT (REED and REED, 1997). The fractions of secondary structure were 
compared with the crystal structures of SA (HYRE et al., 2006) and ST (KORNDORFER and SKERRA, 
2002) (figure 2-13). Both, the line shapes of the CD spectra and the PEPFIT results suggested that all 
proteins shared similar -sheet rates of approximately 44.5 % to 58 % and -helix rates up to 7 % 
(figure 2-13). These minor differences could be explained by small effects of the N-terminal PTD-fusions 
or slight skewing of the analyses of CD spectra due to the need to compensate for the unusually 
pronounced positive peaks at 230 nm (GREEN and MELAMED, 1966). These peaks most likely reflect 
one lobe on an exciton interaction between aromatic side chains (MANDAL et al., 1985; GRISHINA and 
WOODY, 1994). 
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Figure 2-10. Thermal tetramer 
stability of Tat13-SA protein 
preparations: SDS-PAGE analyses of 
Coomassie-stained Tat13-SA proteins 
without ligand or pre-incubated with 
biotin, Strep-tag, or Strep-tag II at 
various temperatures. Tetrameric (T) 
and monomeric (M) states of Tat13-SA 
were indicated. Tetrameric Tat13-SA 
proteins appeared at MWs that differed 
from their theoretical values since the 
electrophoretic mobility strongly 
depends inter alia on the protein 
folding.  
 
 
 
 
 
 
 
 
Legend for figure 2-11 which is printed on the following page. Compilation of thermal tetramer 
stabilities of SA and ST, as well as of Transvidins and Transtactins, either in the absence or presence 
of the ligands biotin, Strep-tag, or Strep-tag II: Tetrameric and monomeric protein amounts less than 10 %, 
with respect to the deployed amount of protein, remained unconsidered. 
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 Temperature [°C] 
PTD SA/ST Ligand 50 55 60 65 70 75 80 85 90 95 99 
-                       
biotin                       
Strep-tag                       
- SA 
Strep-tag II                       
-                       
biotin                       
Strep-tag                       
Tat13 SA 
Strep-tag II                       
-                       
biotin                       
Strep-tag                       
Ant7 SA 
Strep-tag II                       
-                       
biotin                       
Strep-tag                       
R9 SA 
Strep-tag II                       
-                       
biotin                       
Strep-tag                       
TLM12 SA 
Strep-tag II                       
-                       
biotin                       
Strep-tag                       
- ST 
Strep-tag II                       
-                       
biotin                       
Strep-tag                       
Tat13 ST 
Strep-tag II                       
-                       
biotin                       
Strep-tag                       
Ant7 ST 
Strep-tag II                       
-                       
biotin                       
Strep-tag                       
R9 ST 
Strep-tag II                       
-                       
biotin                       
Strep-tag                       
TLM12 ST 
Strep-tag II                       
Tetramer                 
Tetramer / monomer             
Monomer                  
 
 
 
 
 
See previous page for figure legend 2-11 
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Figure 2-12. Far-UV CD spectroscopy: Spectra of SA, ST, Transvidin, and Transtactin proteins showed 
almost identical curve progressions. Note the unusually pronounced peaks at 230 nm which most likely reflect 
one lobe on an exciton interaction. 
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Figure 2-13. Interpretation of CD spectra by PEPFIT analyses: Fractions of the secondary structures were 
compared with the crystal structures of SA (PDB entry 1mk5) (HYRE et al., 2006) and ST (PDB entry 1kl5) 
(KORNDORFER and SKERRA, 2002). 
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THERMAL DENATURATION 
In-line with the data obtained by the temperature-dependent tetramer breakup experiments, thermal 
unfolding analyses using CD spectroscopy revealed that conformational stabilities of SA and ST, as well 
as of individual Transvidins and Transtactins, were consistent with high melting temperatures (Tms). 
These ranged from 74.63 °C for R9-ST to 83.67 °C for SA. Figure 2-14 (A) exemplarily shows the 
thermal denaturation curve for Tat13-SA, figure 2-14 (B) its normalized (see Materials and Methods) 
thermal denaturation curve. All normalized melting curves were summarized in figures 2-14 (C) and (D). 
Table 2-3 shows a compilation of all Tms. 
 
A 
   
B 
 
C 
 
D 
 
Figure 2-14. Thermal denaturation: (A) Thermal denaturation of a Tat13-SA preparation with a Tm of  
80.11 °C. (B) Normalized thermal denaturation curve of Tat13-SA. Compilations of two independently 
determined melting curves of (C) Transvidin and (D) Transtactin proteins. 
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Protein Tm [°C] 
SA 83.67 ± 0.34 
Tat13-SA 80.68 ± 0.91 
Ant7-SA 79.83 ± 1.04 
R9-SA 76.95 ± 0.56 
TLM12-SA 80.77 ± 0.09 
ST 79.21 ± 0.76 
Tat13-ST 76.46 ± 0.37 
Ant7-ST 75.45 ± 1.22 
R9-ST 74.63 ± 1.51 
TLM12-ST 80.74 ± 0.63  
Table 2-3. Thermal denaturation: Compilation of all Tms. 
 
2.3 INTERNALIZATION OF STREPTAVIDIN AND STREP-TACTIN BY PTD-
FUSED LIGANDS 
Next, the above generated tools were tested functionally. The first transmembrane delivery system 
analyzed consisted of two components: (i) SA, as a non-cell permeable model for a protein binder, and 
(ii) PTD-fused Strep-tag II which more weakly interacts with the binding pocket of SA than the 
intracellular target molecule biotin. Hypothetically, upon PTD mediated internalization, Strep-tag II 
should be replaced on SA by biotin (figure 2-15, upper part of the panel). This principle should also be 
applicable for other protein binders (e.g. anticalins (SCHLEHUBER and SKERRA, 2005; SKERRA, 
2007)), acting on defined intracellular targets (figure 2-15, lower part of the panel). 
 
In an initial set of experiments, Tat13-PEO3-biotin was used to internalize SA and to characterize its 
intracellular distribution upon internalization. Analogous experiments were then performed utilizing 
Tat13-Strep-tag II as transporter and SA/ST as cargos. These experiments also addressed the question 
whether the binding affinity of the ligands might influence the efficiency of transmembrane delivery. 
Finally, the intracellular displacement of Tat13-Strep-tag II by biotin was investigated. This latter 
analysis took advantage of the observation that biotin binding leads to an increased thermal tetramer 
stability of SA when compared to Tat13-Strep-tag II complexes (figure 2-11). 
 
INTERNALIZATION OF SA BY TAT13-PEO3-BIOTIN 
INTRACELLULAR DISTRIBUTION 
In general, PTD-mediated internalized cargos appear in two major distribution patterns, either 
cytosolically solubilized or in a punctuated pattern which is likely to reflect endosomal compartments 
(RINNE et al., 2007). Whether the same is true for SA internalized by Tat13-PEO3-biotin was 
investigated by fluorescence microscopy. Titration experiments revealed that externally applied 
concentrations of as low as 100 nM SA complexed with 100 nM Tat13-PEO3-biotin could be visualized 
by immunofluorescence upon internalization (data not shown). For the following experiments, HeLa  
 
Chapter 2 
38 
 
Figure 2-15. Model for the internalization of protein binders by PTD-fused ligands: SA is internalized into 
mammalian cells by PTD-Strep-tag II, most likely via the endosomal route (upper part of the panel). In the 
cytoplasm, PTD-Strep-tag II is replaced by the higher affinity ligand biotin which is internalized by means of the 
multivitamin transporter. If this system is principally functional, one could envision the application of 
therapeutically useful protein binders, e.g. anticalins, using low affinity PTD-ligands for internalization (lower 
part of the panel). Subsequently, this ligand will be replaced by a higher affinity intracellular target molecule, 
leading to the functional inactivation of the latter by sequestration. 
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cells were incubated with 10 µM SA pre-complexed with 10 µM Tat13-PEO3-biotin. Non-complexed SA 
served as negative control. After 2 hours of incubation, cells were trypsinized to remove extracellularly 
attached proteins, plated on glass coverslips for paraformaldehyde (PFA) fixation, and subsequently 
analyzed by immunofluorescence. It was found that Tat13-PEO3-biotin internalized its cargo SA into 
almost 100 % of the HeLa cells (figure 2-16). Control-treated cells showed no internalization. Higher 
resolution microscopy analyses showed that Tat13-internalized SA proteins were typically detected in 
two major intracellular distribution patterns (figure 2-17), either punctuated around the cell nucleus or 
cytosolically solubilized. 
 
 
SA SA + Tat13-PEO3-Biotin  
Figure 2-16. Internalization of SA by Tat13-PEO3-biotin: Internalized SA was detected by 
immunofluorescence analysis. DNA-staining with DAPI in blue, SA is shown in red. 
 
Figure 2-17. Intracellular distribution of SA internalized by Tat13-PEO3-biotin: HeLa cells were treated 
with SA alone (upper panel, negative control) or with SA complexed with Tat13-PEO3-biotin (lower two panels). 
INTERNALIZATION OF SA-FUSION PROTEINS BY TAT13-PEO3-BIOTIN 
To quantify the efficiency of transmembrane delivery, horseradish peroxidase (HRP) fused to SA was 
applied as cargo. HeLa cells were incubated with 1 µM of SA-HRP complexed with 2 µM Tat13-PEO3-
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biotin. High enzymatic HRP-activities were measured only in lysates of HeLa cells treated with SA-HRP 
complexed with Tat13-PEO3-biotin (figure 2-18, upper panel). Untreated cells or cells incubated with 
SA-HRP alone showed only low background enzymatic HRP activities. An SA-HRP calibration curve  
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Figure 2-18. Internalization of SA-HRP by Tat13-PEO3-biotin: Analyses of enzymatic HRP activities in HeLa 
cell lysates (upper panel). Calibration curve of the SA-HRP enzyme activity to determine internalization rates 
(lower panel). 
(figure 2-18, lower panel) was calculated to estimate the amount of Tat13-PEO3-biotin internalized SA-
HRP. Regarding the theoretical maximum amount of internalized SA-HRP, which equaled the molarity 
of the Tat13-PEO3-biotin transporter, 0.74 % of functional SA-HRP were introduced by Tat13-PEO3-
biotin, which equaled 26 pmol per mg total amount of protein (table 2-4). 
 
Transporter and cargo 
Tat13-PEO3-biotin 
SA-HRP 
Quantification 
(0.27 - 1.03) % 
(26 - 72) pmol/mg  
Table 2-4. Quantification of the internalization of SA-HRP by 
Tat13-PEO3-biotin: Internalized amounts of HRP were 
calculated with respect to the theoretical maximum amount of 
internalized SA-HRP in percent or in pmol of internalized SA-
HRP normalized to the total amount of protein (for details, see 
Materials and Methods). 
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INTERNALIZATION OF ST BY TAT13-STREP-TAG II 
INTRACELLULAR DISTRIBUTION 
The internalization efficiency and intracellular distribution of ST internalized by Tat13-Strep-tag II were 
investigated as described for SA and Tat13-PEO3-biotin. Again, HeLa cells treated with complexes of 
ST and Tat13-Strep-tag II were almost 100 % ST-positive, as shown by fluorescence microscopy  
(figure 2-19). Alike SA, the internalized ST, also appeared cytosolically solubilized or in a punctuated 
pattern around the nucleus (figure 2-20). 
 
 
ST ST + Tat13-Strep-tag II  
Figure 2-19. Internalization of ST by Tat13-Strep-tag II: Internalized ST was detected using an anti-SA 
primary antibody. DNA-staining with DAPI in blue, ST is shown in red. 
 
 
Figure 2-20. Intracellular distribution of ST internalized by Tat13-Strep-tag II: HeLa cells were treated with 
ST alone (upper panel, negative control) or in a complex with Tat13-Strep-tag II (lower two panels). 
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INTERNALIZATION OF ST-FUSION PROTEINS BY TAT13-STREP-TAG II 
Tat13-Strep-tag II was also able to internalize functional ST-HRP conjugates. High enzymatic activities 
were detected in lysates of HeLa cells incubated with ST-HRP complexed with Tat13-Strep-tag II (figure 
2-21, upper panel). In contrast, untreated cells showed no enzymatic activity. Cells treated with ST-HRP  
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Figure 2-21. Internalization of ST-HRP by Tat13-Strep-tag II: Analyses of enzymatic HRP activities in HeLa 
cell lysates (upper panel). Calibration curve of ST-HRP (lower panel). 
alone showed only low background enzymatic HRP signals. Regarding the theoretic maximum amount 
of internalized ST-HRP, 0.68 ‰ of ST-HRP were successfully internalized, which equaled 4.2 pmol per 
mg total protein (table 2-5). 
 
Transporter and cargo 
Tat13-Strep-tag II 
ST-HRP 
Quantification 
(0.68 - 0.76) ‰ 
(4.2 - 14) pmol/mg  
Table 2-5. Quantification of the internalization of ST-HRP by 
Tat13-Strep-tag II. 
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The observed range of internalization of ST-HRP by Tat13-Strep-tag II (KD = 1 µM) was lower compared 
to the internalization of SA-HRP by Tat13-PEO3-biotin (KD ~ 10-14 M). This can partly be explained by 
means of the law of mass action (see Materials and Methods). According to that, only 58 % of ST-HRP 
were theoretically complexed with Tat13-Strep-tag II and therefore suitable for cellular internalization. 
 
INTERNALIZATION OF SA BY TAT13-STREP-TAG II AND ST BY TAT13-PEO3-BIOTIN 
Finally, the internalization of SA by Tat13-Strep-tag II and ST by Tat13-PEO3-biotin was tested. Again, 
HeLa cells were almost 100 % SA/ST-positive after treatment with the corresponding complexes, as 
depicted in figure 2-22. Control-treated cells showed no cargo internalization (data not shown). 
Internalized SA and ST proteins appeared in similar distribution patterns (data not shown) as found for 
Tat13-PEO3-biotin and SA (figure 2-17). 
 
 
SA + Tat13-Strep-tag II 
 
ST + Tat13-PEO3-Biotin 
  
Figure 2-22. Internalization of SA by Tat13-Strep-tag II and ST by Tat13-PEO3-biotin: Internalized SA and 
ST proteins were detected by immunofluorescence analyses using anti-SA primary antibodies. DNA-staining 
with DAPI in blue, SA and ST are shown in red. 
Next, the internalization efficiencies of Tat13-Strep-tag II for SA-HRP (figure 2-23, upper panel) and 
Tat13-PEO3-biotin for ST-HRP (figure 2-24, upper panel) were determined as described above. High 
enzymatic HRP-activities were measured only in lysates of HeLa cells incubated with SA/Tat13-Strep-
tag II and ST/Tat13-PEO3-biotin, respectively. Untreated cells or cells incubated with SA/ST-HRP alone 
showed no or low background enzymatic HRP activities. Regarding the theoretical maximum amount of 
internalized HRP, 0.24 ‰ of SA-HRP and 0.62 % of ST-HRP were functionally internalized by Tat13-
fused Strep-tag II and biotin (table 2-6). This equaled 1.5 pmol/mg SA-HRP and 22 pmol/mg ST-HRP, 
respectively. 
 
The observed internalization efficiency for SA-HRP by Tat13-Strep-tag II (KD = 72 µM) was lower than 
for ST-HRP and Tat13-Strep-tag II (KD = 1 µM). This can be partly explained by applying the law of 
mass action. According to that, only 2.7 % of SA-HRP and Tat13-Strep-tag II were theoretically  
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Figure 2-23. Internalization of SA-HRP by Tat13-Strep-tag II: Analyses of enzymatic HRP activities in 
HeLa cell lysates (upper panel). Calibration curve of SA-HRP (lower panel). 
complexed. The internalization efficiencies for ST-HRP (KD < 1 µM, ND) and SA-HRP (KD ~ 10-14 M) by 
Tat13-PEO3-biotin were in a similar range. 
 
LIGAND-REPLACEMENT BY AN INTRACELLULAR TARGET 
According to the model depicted in figure 2-15, Tat13-Strep-tag II will be replaced on internalized SA by 
its natural higher-affinity binding ligand biotin. This should result in increased thermal tetramer stability 
since biotin binding stabilizes SA tetramers (figure 2-11). 
 
To investigate this issue, HeLa cells were first treated with complexes of 10 µM SA and 20 µM Tat13-
Strep-tag II. After 2 hours, the cells were extensively washed and, subsequently, a 2-fold molar excess 
of biotin was added to the cells. Biotin-uptake was supported by means of the mammalian multivitamin 
transporter (PRASAD and GANAPATHY, 2000). After 2 additional hours, cell lysates were prepared and 
analyzed by immunoblotting (figure 2-25, lower panel). 
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Figure 2-24. Internalization of ST-HRP by Tat13-PEO3-biotin: Analyses of enzymatic HRP activities in 
HeLa cell lysates (upper panel). Calibration curve of ST-HRP (lower panel). 
Transporter and cargo Quantification 
SA-HRP 
Tat13-Strep-tag II 
(0.17 - 0.24) ‰ 
(0.56 - 1.5) pmol/mg 
ST-HRP 
Tat13-PEO3-biotin 
(0.62 - 0.87) % 
(22 - 29) pmol/mg  
Table 2-6. Quantification of the internalization 
of SA/ST-HRP by Tat13-fused ligands. 
 
 
As shown in figure 2-11, stabilization of SA tetramers is reflected by decreased amounts of SA 
monomers. In-line with this, intracellular Tat13-SA tetramers (positive control) were thermally stabilized 
by the addition of biotin to the cells, as indicated by the decreased amount of SA monomers at 85 °C 
(figure 2-25, fourth panel). For Tat13-PEO3-biotin internalized SA, external addition of biotin is not 
expected to result in a further stabilization of SA tetramers, since Tat13-PEO3-biotin is a biotin-derivative 
which already strongly binds to the SA pocket. Indeed, upon SA internalization by Tat13-PEO3-biotin, 
the addition of biotin to the cells did not affect the amount of SA monomers at high temperatures (figure 
2-25, third panel). This finding strongly differed from the data for Tat13-Strep-tag II-internalized SA, 
where SA was no longer monomeric at 85 °C upon addition of biotin to the cells (figure 2-25, second 
panel). These results strongly suggest that biotin induced the thermal stabilization of SA tetramers by 
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Figure 2-25. Intracellular replacement of Tat13-Strep-tag II on SA by biotin: (A) Scheme for the 
temperature-dependent tetramer breakup of SA complexed with biotin (red) or Strep-tag II peptide (blue). 
Tetrameric and monomeric SA proteins are indicated. Monomeric SA was investigated to show intracellular 
ligand replacement (yellow). (B) Immunoblot analysis of monomeric SA. Actin: loading control. 
replacing Tat13-Strep-tag II on SA. Thus, the internalization of a protein binder by a low affinity ligand 
fused to a PTD is feasible and can be utilized for subsequent ligand replacement in the cytoplasm. 
 
2.4 INTERNALIZATION OF TRANSVIDINS AND TRANSTACTINS 
PTDs were fused to SA (Transvidins) and ST (Transtactins) in an attempt to convert both proteins into 
universal cell-permeable transporters for biotinylated and Strep-tag II-fused cargos, respectively  
(figure 2-26). To investigate the ability of the transporters to internalize into mammalian cells, HeLa and 
SiHa cervical carcinoma as well as U-2 OS osteosarcoma cells were incubated with 1 µM of individual 
Transvidins and Transtactins for 2 hours. Cells were trypsinized to remove extracellularly attached 
proteins. Subsequently, cell lysates were prepared and analyzed by immunoblotting. Under these 
experimental conditions, Tat13- and R9-fused SA and ST proteins, but not TLM12-SA/ST, internalized at  
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Figure 2-26. Model for the internalization of Transvidins and Transtactins: Cargos bind via biotin- and 
Strep-tag II-fused ligands to Transvidin and Transtactin transporters. The PTD portion of the 
Transvidins/Transtactins mediates the transmembrane delivery of the complexes via the endosomal route 
into mammalian cells. Ligand-fused cargos per se, or ligand-fused cargos bound to unfused SA or ST 
proteins, are not internalized (negative controls). 
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readily detectable levels (figure 2-27). The results for Ant7-fused transporters differed in the fact that the 
Ant7-SA uptake was not detectable by Western blot analysis, in contrast to Ant7-ST. Notably,  
Tat13-SA/ST and R9-SA/ST displayed a more efficient internalization than Ant7-ST (figure 2-27). 
 
 
Figure 2-27. Internalization of Transvidins and Transtactins into HeLa, SiHa, and U-2 OS cells: 
Immunoblot analyses of intracellular monomeric SA/ST proteins upon treatment with the indicated 
transporters. Tubulin: loading control. 
For immunofluorescence analyses, HeLa cells were treated with 10 µM of Transvidins (figure 2-28, 
panels to the left) or 10 µM of Transtactins (figure 2-28, panels to the right). All cells were almost 100 % 
SA/ST-positive, except for TLM12-SA/ST treated cells where the percentage of cells showing 
internalization was below 1 %. SA and ST, lacking PTDs, served as negative controls. 
 
Next, the intracellular distribution of internalized Tat13-SA/ST, Ant7-SA/ST, and R9-SA/ST was 
analyzed. Transvidins (figure 2-29) and Transtactins (figure 2-30) were detected in two major 
distribution patterns, either in a punctuated pattern around the cell nucleus or cytosolically solubilized. In 
the case of unfused SA and ST, serving as negative controls, no internalized proteins were detected. 
Treatment of SiHa or U-2 OS cells yielded identical results (data not shown). 
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SA ST 
 
Tat13-SA Tat13-ST 
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R9-SA R9-ST 
 
TLM12-SA TLM12-ST 
Figure 2-28. Internalization 
efficiencies of Transvidins 
and Transtactins in HeLa 
cells: Immunofluorescence 
analyses using an anti-SA 
primary antibody which 
recognizes both SA and ST. 
DNA-staining with DAPI in 
blue, SA and ST are shown in 
red. 
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Figure 2-29. Intracellular distribution of Transvidins: Larger magnifications of immunofluorescence 
analyses of HeLa cells treated with SA alone (upper panel, negative control) or with Tat13-SA, Ant7-SA, and 
R9-SA proteins (lower panels). Internalized Transvidins were detected using an anti-SA antibody. 
In summary, Tat13-SA/ST and R9-SA/ST proteins fulfilled the required internalization properties, both at 
high and at low applied external doses. Ant7-SA/ST internalization could only be detected at high doses 
(figures 2-29 and 2-30). TLM12 failed as a PTD, since it could not internalize covalently bound SA/ST 
(figures 2-27 and 2-28). Therefore, the following experiments aiming at the concomitant internalization 
of biotinylated or Strep-tag II-fused cargos focused on Tat13-SA/ST, Ant7-SA/ST, and R9-SA/ST 
transporters. 
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Figure 2-30. Intracellular distribution of Transtactins: Larger magnifications of immunofluorescence 
analyses of HeLa cells treated with ST alone (upper panel, negative control) or with Tat13-ST, Ant7-ST, and 
R9-ST (lower panels). Internalized Transtactins were detected using an anti-SA antibody. 
 
2.5 TRANSVIDINS AS UNIVERSAL DELIVERY SYSTEMS FOR BIOTINYLATED 
CARGOS 
Next, the abilities of Transvidins to deliver cargos into intact cells were tested by using biotinylated 
organics, peptides, proteins, and proteinaceous multicomponent complexes. 
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INTERNALIZATION OF FITC-BIOTIN AS A MODEL CARGO FOR ORGANICS 
In order to investigate whether Transvidins were able to co-internalize a biotinylated cell-membrane 
impermeable organic, HeLa cells were treated with 10 µM Tat13-SA, Ant7-SA, or R9-SA complexed with 
10 µM FITC-biotin. Figure 2-31 shows that FITC-biotin was clearly internalized by Transvidin 
transporters. In contrast, cells control-treated with FITC-biotin alone or in a complex with SA (devoid of 
a PTD) showed no FITC fluorescent signals. The staining pattern for FITC-biotin was punctual,  
 
 
 
Figure 2-31. Intracellular distribution of FITC-biotin internalized by Transvidins: Fluorescence 
microscopy of HeLa cells treated with FITC-biotin alone, with FITC-biotin bound to SA (upper two panels, 
negative controls), Tat13-SA, Ant7-SA, or R9-SA (lower panels). TRITC-dextran: fluid-phase endosomal 
marker, which was present in the medium. 
indicating enrichment in distinct cellular compartments. These signals co-stained with TRITC-dextran, a 
fluid-phase endosomal marker, indicating that FITC-biotin was enriched in endosomal compartments. 
 
INTERNALIZATION OF HRP-BIOTIN AS A MODEL CARGO FOR PROTEINS 
Transvidins were also tested for the transmembrane delivery of biotinylated proteins into cultured HeLa 
cells. 200 nM Transvidins were incubated with 400 nM HRP-biotin. High enzymatic HRP activities were 
measured in lysates of cells treated with Tat13-SA and R9-SA (figure 2-32, upper panel). Cells  
 
 
 
Results 
53 
0,0
0,1
0,2
0,3
0,4
0,5
0,6
A
bs
or
ba
nc
e
 
un
tre
at
ed
 
S
A
 
H
R
P
-b
io
tin
 
Ta
t1
3-
S
A
 
H
R
P
-b
io
tin
 
R
9-
S
A
 
H
R
P
-b
io
tin
 
 
 
Figure 2-32. Internalization of functional HRP-biotin by Transvidins: Analyses of enzymatic HRP-biotin 
activities in HeLa cell lysates (upper panel). Calibration curve of HRP-biotin bound to SA (lower panel). 
Transporter and cargo Quantification 
Tat13-SA 
HRP-biotin 
(0.10 - 0.21) % 
(1.6 - 16) pmol/mg 
R9-SA 
HRP-biotin 
(0.10 - 0.23) % 
(1.8 - 9.3) pmol/mg  
Table 2-7. Quantification of the internalization 
of HRP-biotin by Transvidins. 
 
incubated with Ant7-SA or TLM12-SA showed only low enzymatic activities (data not shown). Untreated 
cells and cells treated with complexes of HRP-biotin and SA (devoid of a PTD) showed no or only low 
background enzyme activities (figure 2-32, upper panel, negative controls). R9-SA possessed the 
highest internalization rate of 0.23 % regarding the theoretical maximum amount of internalized HRP-
biotin, which equaled 3.3 pmol per mg total protein (table 2-7). 
 
INTERNALIZATION OF PROTEINACEOUS MULTICOMPONENT COMPLEXES 
Additional experiments were performed to find out whether Transvidins were also able to deliver 
multicomponent complexes into cells. To this end, HeLa cells were incubated with 200 nM Transvidins 
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complexed with 300 nM His6-PEO3-biotin and 400 nM Ni-NTA-HRP. In this scenario, the Ni-NTA-HRP 
portion should be non-covalently linked to Transvidin via His6-PEO3-biotin and internalized. Indeed, high 
enzymatic HRP activities were measured only in cellular lysates of HeLa cells incubated with Tat13-SA 
or R9-SA complexed with His6-PEO3-biotin and Ni-NTA-HRP (figure 2-33, upper panel). Untreated cells 
or cells incubated with a complex of SA (devoid of a PTD), His6-PEO3-biotin, and Ni-NTA-HRP showed 
no or only low background HRP activities. Low enzymatic HRP activities were also measured in lysates 
of HeLa cells incubated with Ant7-SA (data not shown). R9-SA complexed with His6-PEO3-biotin  
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Figure 2-33. Internalization of Ni-NTA-HRP by Transvidins via His6-PEO3-biotin: Analyses of enzymatic 
HRP-activities in HeLa cell lysates (upper panel). Calibration curve of Ni-NTA-HRP bound to SA via His6-
PEO3-biotin (lower panel). 
Transporter and cargo Quantification 
Tat13-SA 
His6-PEO3-biotin 
Ni-NTA-HRP 
(0.11 - 0.40) % 
(2.0 - 16) pmol/mg 
R9-SA 
His6-PEO3-biotin 
Ni-NTA-HRP 
(0.18 - 0.51) % 
(4.9 - 14) pmol/mg 
 
Table 2-8. Quantification of the internalization 
of Ni-NTA-HRP by Transvidins. 
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possessed the highest internalization rate of 0.51 % regarding the theoretical maximum amount of 
internalized Ni-NTA-HRP which equaled 14 pmol per mg total protein (table 2-8). 
 
2.6 TRANSTACTINS AS UNIVERSAL DELIVERY SYSTEMS FOR 
STREP-TAG II-FUSED CARGOS 
Corresponding experiments, as described for Transvidin, were performed to test the potential of 
Transtactin transporters to concomitantly internalize various model cargos into living cells. 
 
INTERNALIZATION OF FITC-STREP-TAG II AS A MODEL FOR ORGANICS 
Strep-tag II-fused FITC served as a model organic to be introduced by Transtactins. Upon treatment of 
HeLa cells with 10 µM Transtactins complexed with 10 µM FITC-Strep-tag II, Tat13-ST, Ant7-ST, and 
R9-ST clearly internalized FITC-Strep-tag II (figure 2-34, lower panels). In contrast, cells control-treated 
with FITC-Strep-tag II alone or with FITC-Strep-tag II complexed with ST (devoid of a PTD) showed no 
FITC fluorescent signals (figure 2-34, upper two panels). Intracellular staining at higher magnification 
was punctual for FITC-Strep-tag II and co-stained with TRITC-dextran, indicating that FITC-Strep-tag II 
was enriched in endosomal compartments (figure 2-34). 
 
 
Figure 2-34. Intracellular distribution of FITC-Strep-tag II internalized by Transtactins: Fluorescence 
microscopy of HeLa cells treated with FITC-Strep-tag II alone or in a complex with ST (upper two panels, 
negative controls), Tat13-ST, Ant7-ST, or R9-ST (lower panels). TRITC-dextran: fluid-phase endosomal 
marker. 
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INTERNALIZATION OF HRP-BIOTIN AS A MODEL CARGO FOR PROTEINS 
The capacity of Transtactins to internalize proteins in an intracellularly functional form was analyzed by 
using HRP-biotin as a cargo (figure 2-35). High enzymatic HRP activities were measured in HeLa cells 
treated with complexes of 1 µM Tat13-ST or 1 µM R9-ST with 2 µM HRP-biotin. In contrast, cells  
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Figure 2-35. Internalization of HRP-biotin by Transtactins: Analyses of enzymatic HRP activities in HeLa 
cell lysates (upper panel). Calibration curve of HRP-biotin bound to ST (lower panel). 
incubated with HRP-biotin alone or in a complex with ST (devoid of a PTD) showed no or only low 
background HRP activities. Regarding the theoretical maximum amount of internalized HRP, 0.22 % of 
HRP-biotin were successfully internalized by R9-ST, which equaled 19 pmol/mg (table 2-9). 
 
Transporter and cargo Quantification 
Tat13-ST 
HRP-biotin 
(0.04 - 0.19) % 
(7.0 - 15) pmol/mg 
R9-ST 
HRP-biotin 
(0.04 - 0.22) % 
(9.0 - 19) pmol/mg  
Table 2-9. Quantification of the internalization 
of HRP-biotin by Transtactins. 
 
Results 
57 
INTERNALIZATION OF PROTEINACEOUS MULTICOMPONENT COMPLEXES AS MODELS FOR 
THERAPEUTIC PEPTIDES AND PROTEINS 
Finally, it was tested whether Transtactins were able to deliver multicomponent complexes into intact 
cells. To this end, HeLa cells were incubated with 1 µM Transtactin proteins complexed with 1.5 µM 
His6-Strep-tag II and 2 µM Ni-NTA-HRP. In this scenario, the Ni-NTA-HRP portion should be non-
covalently linked to Transtactin via His6-Strep-tag II and internalized concomitantly. Indeed, high 
enzymatic HRP activities were measured in lysates of cells treated with Tat13-ST and R9-ST complexed 
with His6-Strep-tag II and Ni-NTA-HRP (figure 2-36, upper panel). Untreated cells and cells incubated 
with a complex of ST (devoid of a PTD) with His6-Strep-tag II and Ni-NTA-HRP showed no or only 
background HRP activities. Regarding the theoretical maximum amount of internalized Ni-NTA-HRP, 
0.24 % of functional Ni-NTA-HRP were successfully internalized by R9-ST which equaled 26 pmol/mg 
(table 2-10). 
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Figure 2-36. Internalization of Ni-NTA-HRP linked to Transtactins via a His6-Strep-tag II peptide: 
Analyses of enzymatic HRP activities in HeLa cell lysates (upper panel). Calibration curve of Ni-NTA-HRP 
bound to ST via His6-Strep-tag II (lower panel). 
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Transporter and cargo Quantification 
Tat13-ST 
His6-Strep-tag II 
Ni-NTA-HRP 
(0.06 - 0.15) % 
(14 - 23) pmol/mg 
R9-ST 
His6-Strep-tag II 
Ni-NTA-HRP 
(0.06 - 0.24) % 
(15 - 26) pmol/mg 
 
Table 2-10. Quantification of the 
internalization of Ni-NTA-HRP by 
Transtactins. 
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Chapter 3: Discussion 
3.1 TRANSMEMBRANE DELIVERY OF CARGOS 
The efficient internalization of therapeutic agents through the plasma membrane remains a major hurdle 
for drug delivery. One way to achieve cell membrane permeability of cargos, such as therapeutic 
agents, is their genetic or biochemical fusion to PTDs (DIETZ and BAHR, 2004). PTDs can internalize 
covalently and non-covalently bound cargos (GROS et al., 2006) in a non-cell-specific manner by a 
fluid-phase endocytotic mechanism (GUMP and DOWDY, 2007). Since their discovery in the late 
1980s, a broad range of bioactive molecules has been successfully delivered into intact cells using 
PTDs (DIETZ and BAHR, 2004).  
 
In this work, two novel transporter systems for the transmembrane delivery of non-covalently bound 
cargos were developed. The first model system was based on non-covalently bound PTD-fused ligands 
which were generated in order to deliver non-modified protein binders acting on intracellular targets. 
Specifically, SA was internalized by its weakly bound ligand Strep-tag II which itself was coupled to a 
Tat13 PTD. After internalization, the intracellular target biotin was sequestered by displacing Tat13-
Strep-tag II in the SA binding pocket. For the second model system, cell permeable SA and ST 
derivatives, termed Transvidins and Transtactins, were developed as universal transporters for biotin- or 
Strep-tag II-linked compounds. Successfully internalized cargos included FITC-biotin and FITC-Strep-
tag II as model compounds for cell-impermeable organics, HRP-biotin as a model protein cargo, and Ni-
NTA-HRP bound to His6-PEO3-biotin or His6-Strep-tag II as models for multicomponent proteinaceous 
complexes. The introduction of Strep-tag II-fused cargos revealed that a KD of 1 µM was sufficient for 
Transtactin-mediated internalization. The introduced HRPs were enzymatically active, showing that both 
Transvidins and Transtactins allowed the internalization of functionally active proteins. Both transporter 
systems developed in this work may thus allow the circumvention of technical obstacles which are 
currently still associated with transmembrane delivery. 
 
3.2 INTERNALIZATION OF NON-MODIFIED CARGOS 
Unlike cell-permeable organics, many macromolecular agents with therapeutic potential cannot 
penetrate cellular membranes, due to their biophysical properties. This is especially true for peptides 
and proteins. Yet, compared to organics, therapeutic proteins possess several theoretical advantages, 
including increased target specificity (LEADER et al., 2008). So far, therapeutic proteins have been 
almost exclusively used to target extracellular molecules, like tumor-specific cell-surface receptors. The 
development of transporter systems which may allow employing proteins as intracellularly active 
therapeutics is thus a topic of intense research efforts (TREHIN and MERKLE, 2004; GUMP and 
DOWDY, 2007). Notably, however, the genetic linkage of PTDs can result in both reduced expression 
and purification levels, as well as in altered biophysical properties of cargos (HONDA et al., 2005). 
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Therefore, the first part of this work concentrated on the design of a transporter system for a non-
modified cargo which is able to bind and sequester an intracellular target. SA was chosen as a model 
molecule to be internalized by the reversible interaction with Strep-tag II-fused PTDs. 
 
INTERNALIZATION OF UNMODIFIED PROTEIN BINDERS BY PTD-FUSED LIGANDS AND SUBSEQUENT 
LIGAND-REPLACEMENT BY AN INTRACELLULAR TARGET 
The components of this system consisted of (i) SA, a model protein binder containing a binding pocket 
for its intracellular target biotin, (ii) the PTD-fused ligand Strep-tag II, a cell-permeable transporter which 
more weakly interacts with the same pocket, and (iii) biotin, which should replace the PTD-Strep-tag II 
ligand at the intracellular level due to its higher binding affinity to SA. Both immunoblot and 
immunofluorescence analyses demonstrated that Tat13-Strep-tag II mediated the successful 
transmembrane delivery of non-covalently bound SA. Moreover, supplemented biotin, internalized by 
means of the mammalian multivitamin transporter (PRASAD and GANAPATHY, 2000), displaced the 
weakly bound Tat13-Strep-tag II as confirmed by an increased thermal tetramer stability of internalized 
SA. Thus, this system allows the internalization of a protein binder which then can be used to sequester 
a given intracellular target with higher binding affinity to the protein binder. 
 
INTRACELLULAR DISTRIBUTION 
The PTD-mediated uptake mechanism is currently a topic of lively discussion. In the case of cationic 
PTDs, like Tat13, it is most likely that the positively charged side chains interact with the anionic 
structure at the cell surface, thereby leading to an increased local concentration of PTDs. This 
subsequently allows entry by a fluid-phase endocytotic mechanism via endosomal compartments 
(BROOKS et al., 2005). Consistent with this proposed mechanism, internalized SA was found in the 
present study either diffusively distributed in the cytoplasm or in a more punctuated pattern 
(ALBARRAN et al., 2005; RINNE et al., 2007). Similar distribution patterns were observed for SA or ST 
internalized by Tat13-PEO3-biotin and for ST internalized by Tat13-Strep-tag II. The internalization of SA 
and ST by Tat13-fused ligands was found to be highly efficient since almost 100 % of the treated cells 
were positive for SA or ST. Similar efficiencies have been reported for the use of other PTDs (LEA et 
al., 2003). 
 
QUANTIFICATION OF THE INTERNALIZATION 
The efficiency of internalization mediated by Tat13-fused Strep-tag II was quantified using functionally 
active HRP fused to SA. It was lower (~ 1 pmol per mg of total cellular protein) than the reported 
efficiency of the internalization of FITC-SA by Tat11-biotin (23 pmol/mg) (EL-ANDALOUSSI et al., 
2007). This lowered amount of internalization could be explained by the twofold increased MW of SA-
HRP (~ 134 kDa) if compared to FITC-SA (~ 60 kDa) and by the law of mass action which describes the 
proportion of theoretically formed complexes. The increased uptake of SA-HRP by Tat13-PEO3-biotin  
(~ 52 pmol/mg) compared to FITC-SA and Tat11-biotin (EL-ANDALOUSSI et al., 2007) could be 
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explained by the increased incubation times and doses applied in the present study, and by the PEO3 
spacer between PTD and biotin which could increase the accessibility of the Tat13 PTD. 
 
ADVANTAGES AND DISADVANTAGES 
The delivery of cargos by the non-covalent binding of PTD-fused ligands has several theoretical 
advantages over the internalization of cargos which are covalently bound to PTDs. Notably, covalent 
linkage of a PTD can lead to reduced expression and purification yields and/or to impaired biophysical 
properties (HONDA et al., 2005). The system developed in the present work avoids these potential 
obstacles since it allows the delivery of a non-modified cargo. Moreover, in contrast to previously 
designed transmembrane delivery systems, such as Tat11-SA (ALBARRAN et al., 2005; RINNE et al., 
2007) or Tat11-fused protein A (MIE et al., 2003; MIE et al., 2006), the transporter employed here is 
less bulky since it only consists of low-MW components: a PTD and a small ligand. Finally, since the 
active site of the internalized cargo is reversibly occupied by the PTD-fused ligand, only molecules 
possessing a higher affinity to the cargo should be able to displace the ligand. Therefore, unwanted 
side-reactions could be reduced. A drawback of the system is the fact that PTD-fused ligands have to 
be newly designed for every cargo, which can be challenging, time-consuming, labor-intensive, and 
expensive. 
 
FUTURE PERSPECTIVES 
The findings in this study for non-modified SA indicate that - in principle - various engineered protein 
binders, such as anticalins (SCHLEHUBER and SKERRA, 2005; SKERRA, 2007) or peptide aptamers 
(HOPPE-SEYLER et al., 2004; BORGHOUTS et al., 2008), could be utilized for the intracellular 
sequestration of a given target molecule. These protein binders could be internalized by a PTD-fused 
molecule which was derived, for instance, from the intracellular target by chemical modification leading 
to reduced binding affinity. After PTD-mediated internalization, this weakly bound PTD-ligand should be 
displaced by the higher affinity intracellular target, as shown here for the replacement of PTD-Strep- 
tag II by biotin. In many cases, the sequestration of the target should ultimately lead to its functional 
inhibition, thereby providing a new strategy to specifically block the intracellular activities of 
pathologically relevant factors.  
 
3.3 TRANSVIDIN AND TRANSTACTIN TRANSPORTERS 
The second delivery system developed in this work was based on cell-permeable SA and ST derivatives 
that internalized biotin- and/or Strep-tag II-tagged cargos. 
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PRODUCTION OF CELL-PERMEABLE TRANSPORTERS 
It is known that PTDs interact with cellular membranes and thereby can diminish the success of both the 
expression and purification of soluble PTD-fused proteins (HONDA et al., 2005). The purification of 
Transvidins and Transtactins from harvested inclusion bodies seemed to prevent these common 
problems since high amounts - ranging from 10 mg to 80 mg per 1 L expression volume - were purified 
for all recombinant proteins in the present studies. Differences in the obtained amounts for individual 
purified proteins could be explained by varying expression levels and by different efficiencies of the 
refolding process. Notably, among the Transvidins and Transtactins, only Ant16-fused SA and ST could 
not be refolded and purified, in contrast to Ant7-fused SA/ST. Although not further explored here, it is 
likely that this differential biochemical behavior is due to activities of the additional N-terminal 9 amino 
acid sequence present in Ant16. 
 
STABILITIES OF TRANSVIDINS AND TRANSTACTINS 
Since covalent PTD linkage can change the biophysical properties of proteins (HONDA et al., 2005), it 
was necessary to analyse possible alterations in the secondary structures of SA and ST upon fusion to 
the various PTDs. It was found that the fusion of Tat13, Ant7, R9, and TLM12 only slightly altered the 
secondary structures of SA/ST, as determined by far-UV CD spectroscopy and subsequent PEPFIT 
analyses. This indicated that both cargos were extremely rigid protein scaffolds and can well tolerate 
different PTD fusions. Thermal unfolding using CD spectroscopy also revealed high thermal stabilities of 
Transvidins and Transtactins, similar to those of unfused SA and ST. This conformational stability is an 
essential requirement for the functionality of the transporters since the biotin- and Strep-tag II-binding 
properties must be retained. In-line with these spectroscopic results, it was found that all engineered 
Transvidin and Transtactin variants exhibited high thermal tetramer stabilities (up to at least 70 °C) 
which is similar to the published thermal tetramer stability of SA (BAYER et al., 1996; WANER et al., 
2004; HUMBERT et al., 2005). This tetramerization of SA and ST proteins (VOSS and SKERRA, 1997) 
is essential to correctly form the biotin- and Strep-tag II-binding pocket which lies in the interface 
between SA and ST subunits, respectively (SANO and CANTOR, 1995). Summed up, these results 
indicate that both Transvidins and Transtactins are conformationally stable within a wide temperature 
range, thereby retaining the binding capacities for their ligands. Under a more practical aspect, these 
findings also imply that no cooling at the bench or during storage and shipping is necessarily required to 
preserve the functionality of these transporters. 
 
INTERNALIZATION AND INTRACELLULAR DISTRIBUTION OF TRANSVIDINS AND TRANSTACTINS 
All Transvidin and Transtactin proteins - apart from TLM12-SA/ST - efficiently induced their own 
internalization into human cell lines which stemmed from epithelial (HeLa, SiHa) or connective tissues 
(U2- OS). This is in-line with previous reports showing that PTD-linked molecules can penetrate into a 
wide range of cell types derived from different histological backgrounds (DIETZ and BAHR, 2004). The 
internalization of Transvidins and Transtactins was highly efficient since almost 100 % of the treated 
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cells were SA/ST-positive. Titration experiments revealed that internalization of Tat13-SA/ST and R9-
SA/ST could be detected upon external applications of doses as low as 100 nM. Immunofluorescence 
analyses revealed that the internalized Transvidin and Transtactin transporters were found either 
diffusively distributed in the cytoplasm or in a more punctuated pattern, the latter most likely reflecting 
endosomal compartments, as previously described for other PTD-linked molecules (BROOKS et al., 
2005; RINNE et al., 2007). 
 
INTERNALIZATION OF CARGOS 
Likewise, FITC-labeled biotin and Strep-tag II internalized by Tat13-SA/ST, Ant7-SA/ST, and R9-SA/ST 
transporters co-stained with the fluid-phase endosomal marker TRITC-dextran, supporting the idea that 
the transporters enter cells via the endosomal route. In addition to FITC, serving as an example of a 
small organic compound, Transvidins and Transtactins were even able to internalize proteins (HRP-
biotin) or proteinaceous complexes (His6-PEO3-biotin or His6-Strep-tag II peptides complexed with  
Ni-NTA-HRP). This indicates that both transporter systems should be useful for a multitude of 
applications. Since internalization strongly depends on the properties of the cargo (TUNNEMANN et al., 
2006), one would expect that lower MW cargos will be favorably internalized by Transvidin and 
Transtactin transporters as opposed to larger compounds or multicomponent complexes. Notably, 
however, even bulky HRP cargos, with a total MW of up to 160 kDa, were internalized by Transvidin 
and Transtactin transporters. The internalization efficiencies depended on the transporter used, the 
cargo employed, and the doses employed for the treatment of the cells. Internalization for HRP ranged 
between 1.6 pmol and 26 pmol per mg protein which was within the same range as reported for Tat11-
biotin-internalized FITC-SA (EL-ANDALOUSSI et al., 2007). As previously reported for other PTD-fused 
cargos (MITCHELL et al., 2000; FUTAKI et al., 2001), the internalization efficiencies of individual 
Transvidins and Transtactins also increased with a rising number of positively charged residues within 
their PTD portions (Ant7 < Tat13 < R9). 
 
ADVANTAGES AND DISADVANTAGES 
In general, the application of Transvidins and Transtactins is straightforward. Only a short incubation 
step of the transporter with the cargo in buffer conditions is necessary for complex formation. Then, the 
complex is injected into a serum- and biotin-free medium of cultured cells. Free biotin in the cell culture 
medium can be removed with avidin, a biotin-binding protein that does not interfere with Strep-tag II 
(SCHMIDT and SKERRA, 2007). No further treatment or expensive laboratory equipment is required for 
internalization. 
 
Under functional aspects, the transmembrane delivery of cargos by Transvidins and Transtactins bears 
several advantages above the introduction of cargos which are directly linked to PTDs. For example, 
PTD-fused agents have been shown to penetrate intact skin (ROTHBARD et al., 2000; JIN et al., 2001; 
PARK et al., 2002) which indicates that they could pose a health risk for experimentators working with 
potentially hazardous compounds. The fact that - for the use of Transvidins and Transtactins - the 
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transporter and the cargo can be produced separately should increase the bio-safety during 
preparation, since (i) SA and ST have no reported biological functions apart from their biotin-binding 
properties and (ii) the cargo cannot penetrate into cells without the transporter.  
 
Furthermore, both Transvidins and Transtactins should possess advantages over existing cargo 
delivery systems: Firstly, up to four different cargos can be theoretically internalized simultaneously by 
using the homotetrameric Transvidins and Transtactins, in contrast to the previously described R8-Ni-
NTA transporter (FUTAKI et al., 2004) which carries only one binding site for His6-fused cargos. This 
distinction should allow Transvidins and Transtactins to co-transport pH-sensitive endosomal releasing 
polymers like PPAA (ALBARRAN et al., 2005) or peptides like HA2 (WADIA et al., 2004) to enhance 
cytoplasmic delivery (figure 3-1). To avoid cross-linking of the transporters in the case of dimeric or  
 
 
Figure 3-1. Enhanced endosomal release by pH-sensitive polymers: Loading of tetravalent Transtactin 
with both the cargo-ligand and a release polymer-ligand which should disrupt endosomal membranes and 
thereby further increases cytoplasmic delivery. 
multimeric cargos, SA could be replaced by a monovalent SA derivative bearing only one biotin-binding 
site (HOWARTH et al., 2006). Secondly, Transtactins possess advantages over Tat11-SA (ALBARRAN 
et al., 2005; RINNE et al., 2007) or Transvidin transporters. Specifically, the ST/Strep-tag II system has 
become very common for the purification of various cargos, since the Strep-tag II sequence can be 
easily fused to the N- or C-terminus of any kind of recombinant protein during subcloning and Strep- 
tag II-expression vectors are available for a broad variety of host organisms (SCHMIDT and SKERRA, 
2007). Thus, no elaborate chemical linkage, as in the case of biotin, is necessary. Notably, biotinylation 
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may disturb cargo functions due to the chemical linkage, unlike Strep-tag II (SCHMIDT and SKERRA, 
2007). In addition, biotinylation often requires spacer arms between biotin and the cargo to reduce steric 
hindrance. However, typical spacers used for biotinylation, such as a 6 carbon spacer (HNATOWICH et 
al., 1987), can reduce the solubility of the cargo in aqueous media which is problematic for in vivo 
applications where organic solvents cannot be used. In contrast, Strep-tag II requires, if at all, only a 
short two-amino-acid spacer to ensure accessibility (SCHMIDT and SKERRA, 2007). Thirdly, in contrast 
to the PTD-fused protein A transporter developed before (MIE et al., 2003; MIE et al., 2006), no cargo-
specific antibody as linker between the transporter and the cargo is required for the use of Transvidins 
and Transtactins. 
 
TRANSVIDINS AND TRANSTACTINS: FUTURE PERSPECTIVES 
Apart from biotinylated cargos or cargos bearing an SA-binding peptide (e.g. Strep-tag II), it is also 
conceivable to employ Transvidins and Transtactins in order to internalize alternatively tagged proteins. 
This could be achieved by employing suitable linkers, e.g. using Ni-NTA-biotin (O'SHANNESSY et al., 
1995; MCMAHAN and BURGESS, 1996; REICHEL et al., 2007) or Ni-NTA-Strep-tag II for polyhistidine-
tagged proteins (figure 3-2). 
 
 
Figure 3-2. Model for the internalization of polyhistidine-fused cargos by Transvidin: His6-fused cargos 
bind via Ni-NTA-biotin linkers to Transvidin transporters and are concomitantly internalized (right part of the 
panel). Similarly, the internalization of His6-fused cargos by Transtactins via Ni-NTA-Strep-tag II or Ni-NTA-
biotin linkers is also conceivable (not shown). 
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Apart from the described internalization of non-cell-permeable organics, peptides, proteins, and 
proteinaceous complexes, it also could be envisioned to use both transporters for the internalization of 
biotinylated nucleic-acid-based therapeutic agents, such as siRNAs (MEADE and DOWDY, 2007) or 
antisense molecules (WANG et al., 2007). 
 
The intracellular activity of a cargo internalized by Transvidin and Transtactin might be impaired by 
steric problems due to the transporter/ligand complex formation. However, as shown in the present work 
for Tat13-Strep-tag II and SA, it is possible to increase the release of a cargo by adding a higher affinity 
ligand, such as biotin. The same should be true for Strep-tag II-fused cargos internalized by 
Transtactins (figure 3-3). Furthermore, the usage of cleavable linkers possessing for instance a 
reducible disulfide bond (FEENER et al., 1990) or an endosomal and/or cytosolic cleavage site 
(KELLER et al., 2001) could as well increase the release of cargos in the cytoplasm after internalization 
by Transvidins and Transtactins. 
 
 
Figure 3-3. Internalization of Strep-tag II-fused cargos by Transtactin with subsequent cargo-release: 
Strep-tag II-fused cargos are displaced after the supplementation of biotin which is internalized by means of 
the mammalian multivitamin transporter. 
 
 
Discussion 
69 
In summary, Transvidins and Transtactins meet the requirements for universal delivery systems for 
biotinylated, Strep-tag II-, His6-, or Ni-NTA-fused cargos. They thus fill the remaining gap between 
unspecific traditional transfection methods and cell-surface receptor-mediated endocytosis of ligand-
fused cargos. Possible applications of Transvidins and Transtactins range from basic proteomics 
research to high-throughput testing of non-cell permeable intracellularly active diagnostics (SAWYER et 
al., 2003; HONDA et al., 2005) and therapeutic peptides (BORGHOUTS et al., 2005; PRIVE and 
MELNICK, 2006) and proteins (COLAS, 2000; HOPPE-SEYLER et al., 2004; BORGHOUTS et al., 
2008) like antibodies (ADAMS and WEINER, 2005), their fragments (HOLLIGER and HUDSON, 2005), 
and non-antibody-derived binders (BINZ et al., 2005). Since PTDs penetrate the epidermis and dermis 
(ROTHBARD et al., 2000; JIN et al., 2001; PARK et al., 2002), Transvidin and Transtactin transporters 
could also enable the transdermal delivery of concomitantly bound diagnostic and therapeutic agents 
upon in vivo topical applications. 
 
3.4 THERAPEUTIC IMPLICATIONS 
Both the transmembrane delivery of protein binders as well as the utilization of the 
Transvidin/Transtactin transporter systems should bear therapeutic potential. However, due to the 
proteinaceous nature of these molecules, this issue currently still faces many technical hurdles which 
are associated with protein therapeutics in general. These include proteolytic instability of PTDs 
(FUCHS and RAINES, 2005) and antigenicity of SA (BREITZ et al., 2000). Possible solutions to reduce 
the potential antigenicity of Transvidins and Transtactins include site-directed mutagenesis of solvent-
exposed side chains, as shown for SA (MEYER et al., 2001), or replacement of SA/ST by non-
immunogenic protein binders, like human-derived lipocalins (SKERRA, 2000; SCHLEHUBER and 
SKERRA, 2005), engineered to bind protein tags, such as Strep-tag II or His6 (LAZAR, 2007). 
 
For some therapeutic applications, the delivery of cargos into the cell nucleus will be required. 
Internalization into the cell nucleus could be realized by utilizing nuclear localization sequences (NLSs) 
(ESCRIOU et al., 2003), such as the simian virus 40 (SV40) T large antigen NLS-sequence (CARTIER 
and RESZKA, 2002). The NLS could be inserted between the PTD and the SA/ST portion of Transvidin 
and Transtactin transporters with a prefixed cytosolic cleavage site (KELLER et al., 2001) to release the 
PTD into the cytoplasm after successful transmembrane delivery. 
 
Moreover, PTDs internalize cargos receptor-independently into a variety of mammalian and human cell 
types (DIETZ and BAHR, 2004). Due to this lack of cell specificity, PTDs are restricted to local or topical 
applications which could be a major drawback for clinical applications (VIVES et al., 2008). Attempts 
have been made to target PTDs to certain cell types. For instance, Jiang et al. linked the R9 PTD via a 
hairpin loop exhibiting a matrix metalloprotease cleavage site to its polyanionic counterpart through ionic 
interactions (JIANG et al., 2004). Tumor cells that have overexpressed matrix metalloproteases at the 
cell surface can cleave the recognition site. This leads to the drift-away of the polyanionic counterpart. 
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Figure 3-4. Targeted delivery of PTDs: The PTD is temporarily shielded (e.g. by an anionic counterpart) until 
cleavage by a protease. Specific proteases can be present on tumor cells or targeted to disease-related cell 
surface antigens via protein binders (e.g. antibodies): “ADEPT - antibody-directed enzyme prodrug therapy”. 
The PTD is finally unshielded and mediates the local internalization of cargos. In a similar setting, 
cationic PTDs fused to ligands for the internalization of non-modified cargos (figure 3-4) or of the 
various Transvidin and Transtactin transporters could be shielded in a similar way for a cell-specific 
internalization of cargos. 
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Chapter 4: Materials and methods 
4.1 MATERIALS 
ESCHERICHIA COLI-K12-STRAINS 
TG2 E. coli supE hsd5 thi (lac-proAB) (srl-recA)306::Tn10(tetr) 
(SAMBROOK and RUSSELL, 2001) 
BL21(DE3) E. coli B F- dcm ompT hsdS(rB- mB-) gal  (DE3) 
(Stratagene, Heidelberg, Germany) 
 
PLASMID 
pET-21a Novagen, Darmstadt, Germany 
 
OLIGONUCLEOTIDES 
MM-SA-ST-For 5’-  G ACC GGT ACC TAC ATC GGT GCG AGG GGT AAC GCT GAA  
       TC -3’ 
MM-SA-ST-Rev 5’- GA TTC AGC GTT ACC CCT CGC ACC GAT GTA GGT ACC GGT  
       C  -3’ 
MM-Ant16-For 5’-  G GAA TTC CAT ATG CGC CAG ATT AAG ATT TGG TTC CAG  
       AAC CGC CGC ATG AAG TGG AAG AAG GGT GCT GAA GCT  
       GGT ATC ACC GGC ACC -3’ 
MM-Ant7-For 5’-  G GAA TTC CAT ATG CGT CGT ATG AAG TGG AAG AAG GGT  
       GCT GAA GCT GGT ATC ACC GGC ACC -3’ 
MM-Tat13-For 5’-  G GAA TTC CAT ATG TAC GGA AGA AAG AAG CGC AGA CAA  
       AGA AGA CGT CCA CCA GGT GCT GAA GCT GGT ATC ACC  
       GGC ACC -3’ 
MM-R13-For 5’-  G GAA TTC CAT ATG AGA CGC AGA AGA CGC AGA AGA CGC  
       AGA AGA AGA AGA AGA GGT GCT GAA GCT GGT ATC ACC  
       GGC ACC -3’ 
MM-R9-For 5’-  G GAA TTC CAT ATG AGA CGC AGA AGA AGA AGA AGA CGC  
       AGA GGT GCT GAA GCT GGT ATC ACC GGC ACC -3’ 
MM-TLM12-For 5’-  G GAA TTC CAT ATG CCC TTA TCG TCA ATC TTC TCG AGG  
       ATT GGG GAC CCT GGT GCT GAA GCT GGT ATC ACC GGC  
       ACC -3’ 
MM-SA-Rev 5’-    CGC AAG CTT TTA TTA GGA AGC AGC GG -3’ 
 
Underlined nucleotides denote mutations for amino acid substitutions or PTD sequence insertions. 
Oligonucleotides were supplied by the Oligonucleotide Synthesis Core Facility of the German Cancer 
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Research Center (Heidelberg, Germany) or by MWG Biotech (Ebersbach, Germany). All 
oligonucleotides were purified by reversed-phase (RP) high-performance liquid chromatography (HPLC) 
and solved in water. 
 
PROTEINS AND ENZYMES 
Benzonase Merck, Darmstadt, Germany 
Biotin-HRP Pierce, Rockford, IL, USA 
BSA New England Biolabs, Schwalbach, Germany 
CIAP Fermentas, St. Leon-Roth, Germany 
Cytochrom c Bruker Daltonics, Bremen, Germany 
Myoglobin Bruker Daltonics 
Ni-NTA-HRP Qiagen, Hagen, Germany 
PfuUltra polymerase, hotstart (2.5 U/µL) Stratagene 
Restrction endonucleases New England Biolabs 
Fermentas 
Promega, Mannheim, Germany 
SA-HRP Pierce 
ST-HRP IBA, Göttingen, Germany  
T4 DNA ligase (5 U/µL) Fermentas 
Taq DNA polymerase (5 U/µL) Invitrogen, Karlsruhe, Germany 
Ubiquitin Bruker Daltonics 
 
CHEMICALS 
Molecular biology grade reagents and buffer components were used where possible. Otherwise the 
purest materials available were chosen. 
 
Acetonitrile Karl Roth, Karlsruhe, Germany 
Acetic acid Merck 
Adenosine 5’-triphosphate Gibco BRL, Eggenstein, Germany 
Agar-agar Karl Roth 
Agarose Sigma-Aldrich, Taufkirchen, Germany 
Ammonium persulfate Karl Roth 
Ammonium sulfate Karl Roth 
Ampicillin Sigma-Aldrich 
-Androsterone Sigma-Aldrich 
Biotin Sigma-Aldrich 
Bradford working solution Amersham, Braunschweig, Germany 
Bromphenol Blue Sigma-Aldrich 
1-Butanol Applichem, Darmstadt, Germany 
Cesium chloride Applichem 
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Coomassie Blue R-250 Serva, Heidelberg, Germany 
4’,6-Diamidino-2-phenylindole dihydrochloride Roche, Penzberg, Germany 
Dulbecco’s minimal essential medium Gibco BRL 
Dimethyl sulfoxide Merck 
Deoxynucleotide Epicentre, Madison, USA 
Dioxane Sigma-Aldrich 
Di-sodium hydrogen phosphate hexahydrate Fluka, Buchs, Switzerland 
Ethylenediaminetetraacetic acid Acros Organics, Geel, Belgium 
Ethanol Riedel-de Haën, Hannover, Germany 
Ethidium bromide Sigma-Aldrich 
Fetal bovine serum Gibco BRL 
FITC-biotin (Biotin-4-FITC) Sigma-Aldrich 
D(+)-Glucose Applichem 
L-Glutamine Sigma-Aldrich 
Glycerol Gibco BRL 
Glycine GERBU, Gaiberg, Germany 
Guanidine thiocyanate Sigma-Aldrich 
Hydrochloric acid Fluka 
Isopropyl-D-1-thiogalactopyranoside Applichem 
2-Mercaptoethanol Merck 
Lithium chloride  Karl Roth 
Magnesium chloride hexahydrate Merck 
Magnesium sulfate heptahydrate Merck 
Methanol Fluka 
Milk powder, non-fat dry Saliter, Obergünzburg, Germany 
Nonidet P-40 Fluka 
Pefablock Biomol, Hamburg, Germany 
Penicillin-Streptomycin solution Sigma-Aldrich 
Polyacrylamide Karl Roth 
Poly(ethylene glycol) 8000 Sigma-Aldrich 
Potassium acetate Karl Roth 
Potassium chloride Acros Organics, Geel, Belgium 
Potassium dihydrogen phosphate Merck 
2-Propanol Sigma-Aldrich 
Protease inhibitor cocktail P8340 Sigma-Aldrich 
Reporter lysis buffer Promega 
Sodium acetate Merck 
Sodium chloride Riedel-de Haën 
Sodium dodecyl sulfate Bio-Rad, Munich, Germany 
Sodium deoxycholate Sigma-Aldrich 
Sodium hydroxide Mallinchrodt Baker, Griesheim, Germany 
Sucrose Calbiochem 
Sulfuric acid Merck 
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Tetramethylen diamine Sigma-Aldrich 
3,3’,5,5’-Tetramethylbenzidine Pierce 
Trifluoroacetic acid Pierce 
Tris(hydroxymethyl)-aminomethan Sigma-Aldrich 
Trypsin-EDTA Gibco BRL 
Tryptone Difco, Augsburg, Germany 
Tween-20 MP Biomedicals, Eschwege, Germany 
Xylencyanol Sigma-Aldrich 
Yeast extract Difco 
 
KITS 
Plasmid Mini, Midi Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
QuikChange II Site-Directed Mutagenesis Kit  Stratagene 
 
MEDIA, ANTIBIOTICS AND GENERAL SOLUTIONS 
MEDIA AND SOLUTIONS 
All media and solutions for the work with bacteria, proteins, or DNA were autoclaved (20 min, 121 °C) or 
sterilized using 0.22 µm filters (Millipore, Billerica, MA, USA). All solutions were generated with double 
distilled water or with water for injection purposes (B. Braun, Melsungen, Germany) except for culture 
media which were assessed with desalted water. Buffers were pH adjusted utilizing a 761 Calimatic pH-
Meter (Knick, Berlin, Germany). Culture plates were stored at 4 °C, all media and solutions, if not 
otherwise declared, at room temperature (RT). 
 
ANTIBIOTICS 
The following antibiotic stock solution was used: 
 
1000x Ampicillin (Amp)  
100 mg/mL in H2O  
    
The stock solution was sterilized by filtration through a 0.22 µm filter and stored in light-tight containers 
at - 20 °C. 
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MEDIA 
Luria-Bertani (LB) media LB-Agar 
10 g/L Tryptone 10 g/L Tryptone 
5 g/L Yeast extract 5 g/L Yeast extract 
10 g/L NaCl 10 g/L NaCl 
  15 g/L Agar-agar 
The pH was adjusted to 7.0 with NaOH.  
  
Transformation media  
10 % (w/v) PEG 8000   
5 % (v/v) DMSO   
50 mM MgCl2   
15 % (v/v) Glycerol   
 in LB media   
 
LB-agar was autoclaved, gently swirled to distribute the melted agar and after cooling down to 
approximately 50 °C to 60 °C, Amp was added. Between 30 mL to 35 mL of media were poured directly 
from the flask into sterile 90 mm petri dishes (Greiner Bio-one, Frickenhausen, Germany). 
 
PH BUFFERS 
10x Phosphate-buffered saline (PBS) 10x Tris EDTA (TE) 
1.37 M NaCl 100 mM Tris/HCl (pH 8.0) 
27 mM KCl 10 mM ETDA (pH 8.0) 
43 mM Na2HPO4 * 7 H2O   
14 mM KH2PO4   
 
The pH was adjusted to 7.4 with HCl. 
  
 
INDUCTION SOLUTION 
1000x IPTG  
500 mM IPTG in H2O   
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4.2 MOLECULAR BIOLOGY METHODS 
CULTIVATION AND CONSERVATION OF E. COLI STRAINS 
E. coli-K12-strain TG2 was used as a general host for cloning, BL21(DE3) for large-scale protein 
expression of SA and its derivatives. 
 
Single colonies were generated by plating transformed bacteria on LB-agar culture plates and 
incubation for approximately 14 hours at 37 °C. The selection of bacteria for plasmids was carried out 
by the addition of Amp to the medium. Colonies on the plates were checked for identical appearance, 
look, and smell like E. coli. Culture plates with bacterial colonies were stored at 4 °C and used for 
inoculation for up to four weeks. For large-scale protein expression, BL21(DE3) E. coli was freshly 
transformed every time. 
 
Liquid cultures were set up in LB media containing Amp. For precultures, single colonies were picked 
using an inoculating loop and suspended in 5 mL or 50 mL LB media. Main cultures were inoculated 
with a stationary preculture at a ratio of 1:50. Incubation took place at 37 °C and 200 rpm in an SM-30 
culture shaker (Edmund Buehler, Hechingen, Germany). Cell densities were determined by measuring 
the optical density (OD) at a wavelength of 550 nm (OD550) in 1 cm plastic cuvettes (Greiner Bio-One) 
using a GeneQuant spectral photometer (GE Healthcare Biosciences, Munich, Germany). 
 
For conservation of transformed E. coli strains, 0.5 mL of an over-night stationary culture were mixed 
with 0.5 mL of sterile glycerol and stored at - 80°C. 
 
COMPETENT BACTERIA 
Transformation-competent bacteria (HANAHAN, 1985; INOUE et al., 1990) of E. coli strains TG2 and 
BL21(DE3) were prepared by utilizing magnesium-enriched transformation media. Bacterial cells were 
grown in 500 mL LB media until OD550 = 0.5. Cells were pelleted (4000 rpm, 4 °C, 10 min), re-
suspended in 50 mL transformation media, and subsequently frozen in liquid nitrogen (N2, Air Liquide, 
Düsseldorf, Germany). 200 µL aliquots were stored at - 80°C. 
 
TRANSFORMATION OF BACTERIA WITH PLASMID DNA 
Transformation of bacteria with plasmid DNA was performed according to the protocol of Hanahan 
(HANAHAN, 1983). 20 ng to 100 ng of DNA or 5 µL of freshly ligated plasmid DNA were incubated with 
100 µL of competent bacteria. After incubation on ice for 30 min, bacteria were heat-shocked at 42 °C 
for 60 seconds, cooled on ice for 60 seconds, and supplemented with 900 µL LB media. Samples were 
incubated at 37 °C for 1 hour with vigorous shaking using a 1.5 mL thermomixer (Eppendorf, Wesseling-
Berzdorf, Germany) and streaked on Amp-containing LB-agar plates. 
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GEL ELECTROPHORESIS OF DNA 
Double-stranded DNA fragments were separated according to their size by horizontal agarose-gel 
electrophoresis. The DNA was visualized with the fluorescent dye EtBr which intercalates between the 
stacked bases of DNA (MANIATIS et al., 1982). Gel electrophoresis was used for analytical restriction 
analysis, estimation of the quantity, and for the preparative isolation of fragments after restriction digest 
or amplification by PCR. 
 
For analytical agarose gel-electrophoresis, 1 % (w/v) agraose gels were used. Agarose was dissolved in 
TAE buffer at the boiling heat. The molten gel was cooled to approximately 55 °C. After adding  
0.5 µg/mL EtBr, the solution was poured into horizontal gel chambers (Peqlab, Erlangen, Germany). 
After cooling down, the gel was set into a TAE buffer-filled electrophoresis chamber (Peqlab). 1 µg to  
2 µg DNA, supplemented with DNA loading buffer, were loaded per lane and electrophoresis was 
performed at a constant voltage of 90 V (Standard Power Pack P25, Biometra, Göttingen, Germany) for 
1 hour. DNA fragments were visualized in the form of EtBr-intercalats at 312 nm using a UV 
transilluminator system (Konrad Benda, Wiesloch, Germany). Gels were documented using a Gel Jet 
Imager (INTAS, Göttingen, Germany). 
 
For preparative gel electrophoresis, 1.2 % (w/v) agarose gels were poured as described above. Slots 
were loaded with up to 50 µL DNA solution. Electrophoresis took place at 70 V (Standard Power Pack 
P25) for approximately 90 min. Gel cubes were cut out and the DNA fragments were extracted from the 
agarose using the QIAquick Gel Extraction Kit according to the manufacturer’s protocol. 
 
TAE buffer 6x DNA loading buffer 
40 mM Tris 0.25 % (w/v) bromphenol blue 
5 mM sodium acetate 0.25 %(w/v) xylencyanol 
1 mM EDTA (pH 8.0) 30 % (v/v) glycerol 
 
DEPHOSPHORYLATION OF DNA 5’-TERMINI 
The 5’-terminal phosphates of linearized vectors were hydrolyzed with calf intestinal alkaline 
phosphatase (CIAP) in the supplied reaction buffer. Dephoshorylation was carried out in a final volume 
of 50 µL with 5 U of CIAP for 45 min at 37 °C. 
 
CLEAVAGE OF DOUBLE-STRANDED DNA WITH RESTRICTION ENDONUCLEASES 
Restriction endonucleases (REs) were utilized following the supplier’s buffer guidelines. In brief, 
analytical restriction analysis was performed using approximately 1 µg of plasmid DNA in a final volume 
of 20 µL employing 2 µL of 10x appropriate reaction buffer, 2 µL of 10x BSA, and 0.5 µL of RE. The 
reaction was performed at an appropriate temperature for 60 min. REs were heat-inactivated or 
removed using the QIAquick PCR Purification Kit according to the manufacturer’s protocol. 
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DNA LIGATION 
Purified PCR-amplified fragments and digested fragments were subcloned into linearized,  
5’-dephosphorylated plasmid vectors. Ligation of cohesive-end termini was performed by employing T4 
DNA ligase. An amount of 50 ng to 100 ng of vector and a three-fold molar excess of insert were 
incubated with 2 U of T4 DNA ligase in ligation buffer in a final volume of 20 µL in a water bath (Julabo, 
Seelbach, Germany) at 20 °C for 2 hours or over-night at 16 °C. 
 
ETHANOL-PRECIPITATION 
Aqueous DNA solutions were supplemented with 1:10 volume 3 M sodium acetate (pH 5.2) and mixed 
with 2.5-fold volume of ice-cold 100 % ethanol. After incubation at - 20 °C for at least 60 min, the 
precipitated DNA was pelleted (13200 rpm, 4 °C, 15 min). The pellet was washed in 70 % ethanol and 
again pelleted (13200 rpm, 4 °C, 5 min). The pellet was air-dried and dissolved in the appropriate buffer. 
Alternatively, the DNA was purified using the QIAquick PCR Purification Kit according to the 
manufacturer’s protocol. 
 
SITE DIRECTED MUTAGENESIS 
The ST expression vector, comprising the point mutations for the amino acid substitutions E33I, S34G, 
and V36R (numbering according to core SA), was PCR-amplified from the SA expression vector pSA1 by 
one-step PCR mutagenesis following the protocol and primer design guidelines of the QuikChange Site-
directed Mutagenesis Kit manual. In brief, PCR reactions (table 4-1) were performed in 50 µL PfuUltra  
 
Step Cycles Temperature [°C] Time [s] 
1 1 95 120 
95 30 2 18 
55 60 
  68 360 
3 1 4 - 
Table 4-1. Site-directed mutagenesis: Cycling parameters for the QuikChange site-directed mutagenesis 
method to generate ST expression vectors. 
buffer with 50 ng of template, 30 pmol MM-SA-ST-For primer, 30 pmol MM-SA-ST-Rev primer, 1 mM 
dNTPs, and 0.5 µL of PfuUltra DNA polymerase (2.5 U/µL). Subsequently, 1 µL of DpnI endonuclease 
was added, an enzyme specific for methylated DNA and suitable for selectively digesting the parental 
DNA template. After incubating for 1 hour at 37 °C and enzyme removal, 5 µL of the sample were used 
for transformation of E. coli TG2. 
 
ONE-SIDED-OVERLAP-EXTENSION PCR 
The PTD-SA/ST genes were generated by one-sided overlap extension PCR (table 4-2) using overhang  
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Step Cycles Temperature [°C] Time [s] 
1 1 94 120 
94 30 2 20 
52 30 
  68 60 
3 1 68 300 
4 1 4 - 
Table 4-2. One-sided-overlap-extension PCR: Cycling parameters for the PCR to generate PTD-SA/ST 
genes. 
primers containing PTD coding sequences in frame (MM-PTD-For) and the reverse primer MM-SA-Rev. 
PCR reactions were performed in 50 µL Taq buffer with 50 ng of pSA1 or pST1 expression vectors as 
templates, 30 pmol of each primer, 1 mM MgSO4, 0.3 mM dNTPs, and 0.5 µL Taq DNA polymerase  
(5 U/µL). The resulting PCR products flanking NdeI and HindIII restriction sites were ligated into 
linearized pET-21a. 5 µL of the samples were used for transformation of E. coli TG2. 
 
CLONING CONTROL AND SEQUENCING 
Clones were controlled by analytical digestion and sequenced according to the chain termination 
method (SANGER et al., 1977) using double-stranded circular plasmid DNA (CHEN and SEEBURG, 
1985). DNA sequencing was performed by the German Cancer Research Center Sequencing Core 
Facility to confirm correct insertions or presence of mutations. Sequence alignments were generated 
using the online tools ALIGN or CLUSTALW (http://workbench.sdsc.edu). Nucleotide sequences were 
translated into their amino acid sequences using SIXFRAME (http://workbench.sdsc.edu). 
 
EXPRESSION, DENATURATION, AND REFOLDING OF STREPTAVIDIN AND ITS DERIVATIVES 
ST, PTD-SA, and PTD-ST proteins were expressed, denatured, and refolded as published for SA 
(SCHMIDT and SKERRA, 1994). In brief, a single colony of E. coli BL21(DE3) freshly transformed with 
expression vectors for SA or its derivatives was used for inoculating 50 mL LB media containing  
100 µg/mL Amp. After incubation overnight at 37 °C, 20 mL of the pre-cultures were transferred to 1 L of 
the same medium. At an OD550 of 0.6, protein expression was induced by the addition of 0.5 mM IPTG 
and shaking was continued overnight. Cells were pelleted by centrifugation (GSA rotor, Thermo/Sorvall, 
5000 rpm, 15 min, 4 °C) and resuspended in 25 mL ice-cold Tris-buffer A. After centrifugation (GSA 
rotor, 11500 rpm, 30 min, 4 °C), the cells were resuspended in 15 mL ice-cold Tris-buffer B and passed 
through an EmulsiFlex-C5 homogenizer (Avestin, Mannheim, Germany) according to the manufacturer’s 
protocol until complete lysis. The homogenates were centrifuged (GSA rotor, 11500 rpm, 30 min, 4 °C) 
in order to sediment inclusion bodies. After washing with 10 mL ice-cold Tris-buffer B for 15 min, the 
inclusion bodies were dissolved in 8 mL 6 M guanidine/HCl (pH 1.5) in order to remove traces of biotin 
(SANO and CANTOR, 1990). Dissolved inclusion bodies were centrifuged at 15000 rpm at 4 °C for  
15 min (SS34 rotor, Thermo/Sorvall). Refolding was then accomplished by rapid dilution into 250 mL 
PBS buffer at 4 °C. The mixtures were slowly stirred overnight at 4 °C and cleared by centrifugation 
(11500 rpm, 30 min, 4 °C). 
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Tris-buffer A Tris-buffer B 
50 mM Tris/HCl (pH 8.0) 50 mM Tris/HCl (pH 8.0) 
500 mM sucrose 1 mM EDTA 
 
BACTERIAL WHOLE CELL EXTRACTS 
1 mL of Benzonase buffer was supplemented with 12.5 U of Benzonase. 1 mL of culture was pelleted 
(13200 rpm, 1 min, 4 °C) and subsequently dissolved in 75 µL benzonase buffer. Cells were lysed by 
adding 25 µL 4x protein sample buffer. Nucleic acids were hydrolyzed with Benzonase during a 60 min 
incubation step at 4 °C. Whole bacterial cell extracts were stored at - 20 °C until SDS-PAGE. 20 µL of 
protein extract were loaded for a cell culture sample with an OD550 of 0.25. Accordingly, for a cell culture 
sample with an OD550 of OD, a protein extract volume of V was loaded on SDS-polyacrylamide gels 
according to equation (1). 
 
 
OD
V 25.020   [µL]      (1) 
 
4x Protein sample buffer Benzonase buffer 
0.47 M Tris/HCl (pH 6.7) 100 mM Tris/HCl (pH 8.0) 
2 % (w/v) SDS 5 mM MgCl2 
16 % (v/v) glyerole   
6 % (v/v) 2-mercaptoethanol   
0.4 % (w/v) Bromphenol Blue   
 
AMMONIUM SULFATE PRECIPITATION 
Refolded proteins were purified by fractionated ammonium sulfate precipitation as described for SA 
(SCHMIDT and SKERRA, 1994). Solid ammonium sulfate was slowly added to protein solutions in the 
cold to a saturation of 40 % (62.7 g). After slow stirring overnight at 4 °C, the precipitated contaminating 
proteins and monomeric, incompletely refolded SA/ST and PTD-SA/ST proteins, respectively, were 
removed by centrifugation (GSA rotor, 11500 rpm, 30 min, 4 °C). Then, the ammonium sulfate 
saturation was raised to 70 % by adding 59 g. After incubation at 4 °C for 4 hours, tetrameric SA/ST and 
PTD-SA/ST proteins were recovered (GSA rotor, 11500 rpm, 60 min, 4 °C) and resuspended in 9 mL of 
PBS-buffered 2.2 M ammonium sulfate solution for removal of residual impurities which became soluble 
under these conditions. After centrifugation (SS34 rotor, 15000 rpm, 30 min, 4 °C), the recombinant 
proteins were dissolved in 8 mL PBS buffer. The solutions were finally cleared by centrifugation  
(15000 rpm, 30 min, 4 °C). The protein concentrations were adjusted to 1 mg/mL. After sterile filtration 
using a 0.22 µm filter (Millipore), 1 mL aliquots were stored at - 80 °C. Recombinant proteins were 
quality-controlled by SDS-PAGE, MALDI-TOF MS, Edman-sequencing, and far-UV CD spectroscopy. 
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PBS-buffered ammonium sulfate solution   
2.2 M ammonium sulfate   
 in 1x PBS   
 
DETERMINATION OF PROTEIN CONCENTRATIONS 
The concentration of purified proteins was determined by measuring the absorption at 280 nm (A280) 
according to the law of Lambert-Beer where c denoted the protein concentration and d the path length: 
 
 dcA  280       (2) 
 
The extinction coefficients  were determined by means of the program ProtParam (www.expasy.org) 
and are summarized in table 4-3. Protein concentrations were measured with a NanoDrop ND-1000 UV-
Vis spectrophotometer (Thermo). 
 
Protein MW [Da]  [M-1cm-1] Number of 
amino acids 
SA 13271.4 41940 127 
Ant16-SA 15688.4 52940 145 
Ant7-SA 14473.9 47440 136 
R13-SA 15490.1 41940 142 
R9-SA 14865.3 41940 138 
Tat13-SA 15195.7 43430 142 
TLM12-SA 14598.9 41940 140 
ST 13282.5 41940 127 
Ant16-ST 15699.4 52940 145 
Ant7-ST 14485.0 47440 136 
R13-ST 15501.1 41940 142 
R9-ST 14876.4 41940 138 
Tat13-ST 15206.8 43430 142 
TLM12-ST 14610.0 41940 140 
Table 4-3. Theoretical protein parameters: MWs, s, and number of amino acids for all recombinant proteins 
were determined by using the online tool ProtParam at the ExPASy website. 
PEPTIDE SYNTHESIS 
Apart from Strep-tag II (IBA), all peptides (table 4-4) were chemically synthesized at the Peptide 
Synthesis Core Facility of the German Cancer Research Center (Heidelberg, Germany) using Fmoc  
 
Peptide Sequence 
Strep-tag SAWRHPQFGG 
Strep-tag II WSHPQFEK 
FITC-Strep-tag II FITC-WSHPQFEK 
His6-Strep-tag II HHHHHHSAWSHPQFEK 
His6-PEO3-biotin HHHHHH-PEO3-biotin 
Tat13-PEO3-biotin YGRKKRRQRRRPPG-PEO3-biotin 
Tat13-Strep-tag II YGRKKRRQRRRPPGSAWSHPQFEK 
Table 4-4. Peptide syntheses: Sequences of synthetic peptides, given as single-letter amino acids code 
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(N-(9-fluorenyl)methoxycarbonyl) chemistry. Crude peptides were purified by employing C18 RP-HPLC 
and further analyzed by electrospray ionization mass spectrometry (ESI-MS). Measured mol peaks 
were checked for consistency with the expected value. 25 mM peptide stocks in DMSO were stored at  
- 80 °C and freshly diluted in H2O. 
 
PREPARATION OF PROTEIN COMPLEXES 
SA/ST and SA/ST-HRP proteins in PBS were complexed with Tat13-fused Strep-tag II or biotin by 
incubation for 15 min at RT. PTD-SA/ST proteins in PBS were complexed with Strep-tag II- or biotin-
fused cargo molecules under identical conditions. The complexes were directly injected into FBS-free 
DMEM media of cultured cells. 
 
SODIUM DODECYL SULFATE POLYACRYLAMIDE ELECTROPHORESIS 
Protein extracts and purified proteins were separated according to their electrophoretic mobility by SDS-
PAGE. Samples were mixed with 4x protein sample buffer, boiled at 95 °C for 5 min, and loaded into 
slots of small precast vertical slab gel units (Gibco BRL). Two 15 % separation gels were composed of  
5 mL of 30 % (w/v) polyacrylamide, 1.2 mL of separation gel buffer, 3.6 mL of H2O, 100 µL of 10 % (w/v) 
SDS, 100 µL of 10 % (w/v) APS, and 5 µL of TEMED. Two 5 % stacking gels were composed of 830 µL 
of 30 % (w/v) polyacrylamide, 620 µL of stacking gel buffer, 3.47 mL H2O, 50 µL of 10 % (w/v) SDS,  
50 µL of 10 % (w/v) APS, and 5 µL of TEMED. Electrophoresis was performed at a constant voltage of 
65 V (Standard Power Pack P25) for approximately 90 min in running buffer. Gels were stained with 
Coomassie Blue solution and destained with destaining buffer. Gels were stored in storage buffer, 
photographed using a Gel Jet Imager (INTAS), and finally dried on 3 mm Whatman filters paper 
(Schleicher & Schuell, Dassel, Germany) using a model 583 gel dryer (Bio-Rad, Munich, Germany). 
 
Storage solution Staining solution 
7 % (v/v) acetic acid 0.25 % (w/v) Coomassie Blue R-250 
2 % (v/v) glycerol 40 % (v/v) methanol 
  10 % (v/v) acetic acid 
    
De-staining solution Separation gel buffer 
40 % (v/v) methanol 3 M Tris/HCl (pH 8.8) 
10 % (v/v) acetic acid 0.4 % (w/v) SDS 
    
Stacking gel buffer Running buffer 
0.47 M Tris/HCl (pH 6.7) 25 mM Tris/HCl (pH 8.6) 
  192 mM glycine 
 0.1 % (w/v) SDS 
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4.3 BIOPHYSICAL METHODS 
MALDI-TOF MASS SPECTROMETRY 
MS is an analytical technique which can be used for the determination of the MWs of proteins. Protein 
samples were desalted using C4 ZipTip pipette tips (Millipore). Briefly, ZipTips were prewashed with  
0.1 % TFA / 50 % acetonitrile and equilibrated with 0.1 % TFA by repetitive pipetting steps. After loading 
of the protein samples, ZipTips were washed three times with 0.1 % TFA to remove salts. For MALDI-
TOF MS, 0.3 µL of a saturated solution of sinapinic acid in ethanol were deposited as thin film onto 
individual spots of a MALDI target plate. Subsequently, proteins were eluted from the ZipTips with  
1 µL to 2 µL of a saturated solution of sinapinic acid in 0.1 % TFA / 50 % acetonitrile, directly loaded on 
top of the thin film spots and allowed to co-crystallize slowly at ambient temperature. MALDI mass 
spectra were recorded in the positive ion linear mode with delayed extraction on a Reflex II TOF 
instrument (Bruker-Daltonik) equipped with a SCOUT-26 probe and a 337 nm nitrogen laser. Ion 
acceleration voltage was set to 20.0 kV and the first extraction plate to 17.1 kV. Mass spectra were 
obtained by averaging up to 200 individual laser shots. Spectra were calibrated externally by a quadratic 
fit using the singly protonated average masses of ubiquitin I at m/z 8565.89, cytochrom c at  
m/z 12361.55, and myoglobin at m/z 16952.55. MH+(av) values were calculated using the online tool 
ProteinProspector v 4.27.1 (http://prospector.ucsf.edu/). 
 
EDMAN-SEQUENCING 
N-terminal amino acid sequence analyses were performed by Edman-sequencing (GRANT et al., 1997). 
Aliquots of protein samples were spotted on TFA-treated filters (Applied Biosystems, Darmstadt, 
Germany), dried under N2 stream and introduced into a cartridge of an ABI Procise 494 Sequencer 
(Applied Biosystems) followed by N-terminal Edman sequencing performed with a pulsed-liquid 
program. 
 
THERMAL TETRAMER STABILITY 
3 µg of purified SA protein or its derivatives without or with a 2-fold molar excess of biotin, Strep-tag, or 
Strep-tag II were combined with SDS-containing sample buffer and heated at selected temperatures for 
5 min, then chilled on ice until SDS-PAGE. Gels were stained with Coomassie Blue solution and de-
stained with destaining buffer as described. 
 
CIRCULAR DICHROISM SPECTROSCOPY 
CD relies on the differential absorption of left and right circularly polarised radiation by chromophores 
which either possess intrinsic chirality or are placed in chiral environments. Proteins possess a number 
of chromophores which can give rise to CD signals (KELLY and PRICE, 2000). In the far-UV region 
(180 nm to 240 nm), which corresponds to peptide bond absorption, the CD spectrum can be analyzed 
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to determine the fractions of the secondary structure. CD spectroscopy was carried out using a J-710 
spectropolarimeter (JASCO, Gross-Umstadt, Germany) calibrated with a solution of 0.05 %  
-androsterone dissolved in dioxane. Sample temperature control during measurement was achieved 
by using a JASCO PFD-350S peltier thermostat. Samples at a concentration of ~ 100 g/mL protein in 
distilled water were scanned in a 1 mm quartz cuvette from 190 nm to 240 nm for secondary structure 
determination. CD spectra were subtracted from identically scanned and signal-averaged solvent 
baselines. Final spectra were the result of four-fold signal averaging. CD spectra were normalized for 
the mean residue weight (MRW) according to equation (3). 
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MRW denoted the molar ellipticity, obs the measured ellipticity, MR the molecular mass of the protein,  
c the protein concentration, d the path length of the quartz cuvette, and NA the number of the amino 
acids. Spectra were finally plotted with Kaleidagraph (Synergy Software, Reading, PA, USA).  
 
Secondary structure contents were calculated from the far-UV CD spectra. After their conversion to 
mean residue ellipticity (MRW) and removal of residual noise, the program PEPFIT (a Fast Fourier 
Transform program specifically designed for the secondary structure analysis of peptides rather than 
globular proteins) (REED and REED, 1997) was employed for the fitting of the processed spectra. 
 
To determine differences in the thermal stabilities between SA and its derivatives, thermal denaturation 
spectra were run from 40 °C to 95 °C at a gradient of 1.0 °C per min. It was paid attention to the fact 
that all relevant parameters were identical for all protein samples measured since such properties as the 
Tm are not absolute and vary with measurement conditions. Due to the unusual spectral characteristics 
of SA and its related proteins, the observational wavelength for temperature denaturation was chosen to 
be 215 nm rather than the standard 222 nm. Raw data were fit by nonlinear regression to an equation 
for a two-state transition using Kaleidagraph according to equation (4) (BRUMANO et al., 2000). 
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yobs denoted the ellipticity, T was the temperature, R was the gas constant, Tm was the transition 
temperature, and Hm was the enthalpy of unfolding at Tm (van’t Hoff enthalpy). bN and bU referred to 
the y intercepts of the native and unfolded baselines, respectively, while mN and mU were the slopes of 
the baselines. To compare the transitions, each unfolding curve was normalized to the apparent fraction 
of the unfolded form f(u) according to equation (5) (BRUMANO et al., 2000). 
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4.4 CYTOLOGY METHODS 
CELL CULTURES 
Human cell lines (table 4-5) were maintained in Dulbecco’s minimal essential medium (DMEM), 
supplemented with 10 % fetal bovine serum (FBS), 1 % Penicillin-Streptomycin sulfate solution and  
 
Cell line Description Reference 
HeLa HPV18 cervix epithelial adenocarcinoma ATCC CCL-2 
SiHa HPV16 cervix squamous cell carcinoma ATCC HTB-35 
U-2 OS osteosarcoma ATCC HTB-96 
Table 4-5. Human cell lines: Overview of human cell lines and their tissue origin. ATCC (American Type Cell 
Culture Collection, Rockville, MD, USA) catalogue numbers are given. 
1 % of 200 mM L-glutamine solution at 37 °C in 5 % CO2 atmosphere. For routine passage, cells 
reaching confluence were split in ratios between 1:5 and 1:20, generally every 3 days, employing 
trypsin-EDTA solution. 
 
WHOLE CELL EXTRACTS 
The cells were washed and re-suspended by trypsination. After threefold washing with PBS, cells were 
lysed with RIPA buffer supplemented with 1 % P8340 protease inhibitor cocktail and 4 % Pefablock. 
After 30 min on ice, cell extracts were centrifuged (13200 rpm, 4 °C, 5 min) and the supernatants were 
collected. Protein extracts were stored at - 80 °C. 
 
RIPA buffer  
10 mM Tris/HCl (pH 7.5)   
150 mM NaCl   
1 mM EDTA   
1 % (v/v) Nonidet P-40   
0.5 % (w/v) sodium deoxycholate   
0.1 % (w/v) SDS   
 
BRADFORD ASSAY AND SAMPLE PREPARATION 
Protein concentrations in cell extracts were estimated by the method of Bradford (BRADFORD, 1976).  
1 µL of the supernatant was added to 999 µL of Bradford working solution (1:5 dilution of Bio-Rad 
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reagent in water, Bio-Rad), mixed, and incubated for 2 min. Subsequently, absorbance of the solution at 
595 nm was measured with a spectrophotometer (GeneQuant). Absorbance values were converted into 
protein concentrations on the basis of a BSA calibration curve. Cell extracts were adjusted to a protein 
concentration of 3 µg/µL by adding appropriate volumes of RIPA buffer and 4x protein sample buffer. 
Samples were stored at - 80 °C for further analysis. 
 
WESTERN BLOTS 
HeLa, SiHa, and U-2 OS cells were plated on 35 mm or 60 mm dishes (Greiner Bio-one) at 60 % to  
90 % confluence. Proteins and complexes (tables 4-6 and 4-7) were directly injected into FBS-free 
media of cultured cells. After a 120 min incubation at 37 °C, 5 % CO2, the cells were washed, 
trypsinized, harvested, and lysed. Proteins separated by SDS-PAGE were transferred into a semi-dry 
blotter system (cti, Idstein, Germany) to 0.45 µm Immobilon-P (polyvinylidene fluoride, PVDF) 
membranes (Millipore). In brief, membranes were washed in methanol and subsequently equilibrated in  
 
Transporter Concentration 
[µM] 
Cargo Concentration 
[µM] 
Ligand Concentration 
[µM] 
Tat13-ligand 10 SA 20 Biotin 40 
Tat13-SA 10 - - Biotin 40 
Table 4-6. Ligand replacement: PTD-fused ligands: biotin or Strep-tag II 
Transporter Concentration 
[µM] 
PTD-SA 1 
PTD-ST 1 
Table 4-7. Internalization of PTD-SA/ST transporters 
EMBL buffer together with the gel and Whatman filters. The gel was placed at the cathode side of the 
membrane and embedded between Whatman filters. Protein transfer was performed at a current flow of 
2.24 mA per cm2 gel area (Standard Power Pack P25) for 60 min. 
 
EMBL buffer Blocking buffer 
40 mM Tris/HCl (pH 9.2) 0.2 % (v/v) Tween 20 
39 mM glycine 5 % (w/v) non-fat dry milk 
1.3 mM SDS  in 1x PBS 
20 % (v/v) methanol   
 
Washing buffer   
0.2 % (v/v) Tween 20   
 in 1x PBS   
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ENZYME-LINKED IMMUNODETECTION OF PROTEINS ON WESTERN BLOTS 
For immunodetection of proteins, membranes were blocked overnight at 4 °C in blocking buffer and 
consecutively incubated with the primary antibody (table 4-8) and the appropriate secondary antibody 
conjugated with HRP (table 4-9) to allow detection by enhanced chemiluminescence (ECL). Incubation 
steps were intermitted by rinsing in blocking buffer and washing buffer. Immunoprinted and washed  
 
Primary antibodies Specification Manufacturer 
anti-SA (1:2000) rabbit polyclonal antibody Sigma-Aldrich 
anti-ubulin (1:5000) mouse monoclonal antibody DM1A, CP06 Calbiochem 
anti-Actin (1:100000) mouse monoclonal antibody, AC74 Sigma-Aldrich 
Table 4-8. Primary antibodies: List of primary antibodies used for enzyme-linked immunodetection on 
Western blots 
Secondary antibodies Manufacturer 
goat anti-mouse, HRP-conjugate (1:3000) Promega 
goat anti-rabbit, HRP-conjugate (1:3000) Promega 
Table 4-9. Secondary antibodies: List of secondary antibodies used for immunodetection of proteins by ECL 
membranes were incubated with a freshly prepared 1:1 mixture of detection reagent 1 and 2 
(Amersham) for 1 min and wrapped in cling film. Luminescent light signals were detected by Kodak 
Biomax MR photographic films (Eastman Kodak, Stuttgart, Germany), which were processed in an 
Optimax TR X-ray film processor (Protec, Oberstenfeld, Germany). 
 
IMMUNOFLUORESCENCE 
HeLa, SiHa, and U-2 OS cells were plated on 35 mm dishes at 40 % to 60 % confluence. Complexes 
were prepared according to table 4-10 and directly injected into FBS-free media. Endosomes were  
 
Transporter Concentration [µM] Cargo Concentration [µM] 
Tat13-ligand 10 SA 10 
Tat13-ligand 10 ST 10 
Transvidin 10 - - 
Transtactin 10 - - 
Transvidin 10 FITC-ligand 10 
Transtactin 10 FITC-ligand 10 
Table 4-10. Compilation of the complexes used for immunofluorescence analyses: Ligands: biotin or 
Strep-tag II. 
visualized with the fluid-phase marker TRITC-dextran, as described (RINNE et al., 2007). After a  
120 min incubation at 37 °C, 5 % CO2, the cells were washed, trypsinized, and plated on glass cover-
slips. After approximately 4 hours, cover-slips were washed with PBS, subsequently fixed with 4 % PFA 
for 30 to 60 min, washed twice with PBS, and finally stored in 70 % ethanol at - 20 °C until further 
analysis. For immunofluorescence studies, cover-slips were consecutively incubated at room 
temperature in a wet incubation chamber with blocking buffer, first antibody dilution (table 4-11), and 
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second antibody dilution (table 4-12) in PBS, the latter supplemented with DAPI (Roche). Incubation 
steps were intermitted by washing steps using PBS. For co-localization studies, cover-slips were 
incubated with DAPI in PBS only. Finally, cover-slips were washed in ethanol, dried, and embedded in  
 
Primary antibody Specification Manufacturer 
anti-SA (1:500) rabbit polyclonal antibody against SA Sigma-Aldrich 
Table 4-11. Primary antibody: anti-SA antibody used for immunofluorescence 
Secondary antibody Manufacturer 
goat anti-rabbit, Cy3-conjugate (1:400) Dianova, Hamburg, Germany 
Table 4-12. Secondary antibody: Cy3-labeled secondary antibody used for immunofluorescence 
VectaShield H-1000 mounting medium (Vector Laboratories, Burlingame, CA USA). Cy3-, FITC-, and 
TRITC-signals were detected using a Vanox-T AH-2 epifluorescence microscope (Olympus, Hamburg, 
Germany). Pictures were captured with an F-View camera and analyzed with analySIS^B software (both 
Soft Imaging System, Olympus). 
 
Blocking buffer First antibody dilution 
1 % (w/v) BSA 1 % (w/v) BSA 
2 % (v/v) FBS  In 1x PBS 
 In 1x PBS   
 
HORSERADISH PEROXIDISE ACTIVITY ASSAY 
HeLa cells were plated on 35 mm dishes at 60 % to 90 % confluence. Complexes were prepared 
according to table 4-13 and directly injected into FBS-free media. Cells were incubated at 37 °C, 5 % 
CO2 for 2 hours, then trypsinized, washed with 1x PBS, and lysed with 400 µL 1x RLB (ALBARRAN et 
al., 2005). Cell lysates were incubated at room temperature for 15 min. After vortexing and pelleting, the 
supernatants were stored at - 80 °C. 40 µL of the diluted extracts were mixed with 10 µL 1x RLB. At the 
same time, HRP calibration curves were generated using a series of dilutions of SA/ST-HRP (2 mols 
HRP per SA tetramer, MW ~ 134 kDa) or SA/ST complexed with linker peptides and Ni-NTA-HRP or 
HRP-biotin. 10 µL of the proteins or complexes at different dilutions, ranging from 1:2500 to 
1:64000000, were mixed with 40 µL of dilutions of untreated HeLa lysates. Colorimetric reactions were 
initiated by adding 50 µL of 1-Strep Ultra TMB-ELISA substrate solution (Pierce). The reaction was 
stopped at individual points of time by adding 50 µL of 2 M sulfuric acid and the absorbance was 
measured at 450 nm (Multiskan fx ELISA reader, Thermo). 
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Transporter Concentration [µM] Cargo Concentration [µM] 
Tat13-ligand 1 SA-HRP 2 
Tat13-ligand 1 ST-HRP 2 
Transvidin 0.2 HRP-biotin 0.4 
Transtactin 1 HRP-biotin 2 
Transvidin 0.2 His6-PEO3-biotin Ni-NTA-HRP 
0.3 
0.4 
Transtactin 1 His6-Strep-tag II Ni-NTA-HRP 
1.5 
2 
Table 4-13. Compilation of the complexes used for quantification of the PTD-mediated internalization: 
Ligand: biotin or Strep-tag II 
Calibration curves of HRP were fitted using the four parameter logistic (4PL) equation in SigmaPlot 10.0 
(Systat Software, Erkrath, Germany): 
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A denoted the absorbance, I was the input in ng, max and min denoted the top and bottom of the curve, 
H was the hillslope and characterized the slope of the curve at its midpoint, and EC50 was the median 
effective concentration. 
 
The determined absorbance was recalculated to the amount of PTD-mediated internalized HRP using 
equation (6). Finally, the efficiencies (Q1/2) of PTD-mediated internalization of at least two independent 
experiments were calculated, firstly, with respect to the theoretical maximum amount of internalized 
HRP (HRPdeployed), which equaled the molarity of the transporter (without application of the law of mass 
action), using equation (7) and, secondly, with respect to both the actual amount of internalized 
functional HRP and normalized to the amount of total protein using equation (8) (EL-ANDALOUSSI et 
al., 2007). HRPintern denoted the measured functional amount of internalized enzyme. The total protein 
concentration B was estimated by the method of Bradford. 
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The amount of theoretically formed complexes consisting of SA/ST-HRP and Tat13-fused ligands was 
calculated by means of the law of mass action according to equation (9). 
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PL denoted the concentration of the formed complexes, L0 and P0 were the initial concentrations of the 
ligand and the protein, whereas KD was the dissociation constant. 
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Abbreviations and symbols 
IUPAC/IUB SYMBOLS 
The following one-letter code for amino acids was utilized (table 5-1), as declared by the International 
Union of Pure and Applied Chemistry (IUPAC) and the International Union of Biochemistry (IUB). 
 
One-letter code Amino acid 
A Alanine 
C Cysteine 
D Aspartic acid 
E Glutamic acid 
F Phenylalanine 
G Glycine 
H Histidine 
I Isoleucine 
K Lysine 
L Leucine 
M Methionine 
N Asparagine 
P Proline 
Q Glutamine 
R Arginine 
S Serine 
T Threonine 
V Valine 
W Tryptophan 
Y Tyrosine 
Table 5-1. List of amino acids and their corresponding one-letter symbols. 
 
IUPAC FORMULAS 
The following IUPAC formulas for chemical compounds have been utilized in this work: 
 
H2O  Water 
HCl  Hydrochloric acid 
KCl  Potassium chloride 
KH2PO4  Potassium dihydrogen phosphate 
MgCl2  Magnesium chloride 
MgSO4  Magnesium sulfate 
NaCl  Sodium chloride 
Na2HPO4  Di-sodium hydrogen phosphate 
NaOH  Sodium hydroxide 
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ABBREVIATIONS 
Commonly used abbreviations from the fields of biology, chemistry, and biophysics which have been 
utilized in this work are listed below in alphabetic order: 
 
4PL  Four parameter logistic 
A  Absorbance 
A280  Absorption at 280 nm 
ADEPT  Ab-directed enzyme prodrug therapy 
Amp  Ampicillin 
Ant  Antennapedia 
AP  Alkaline phosphatase 
APS  Ammonium persulfate 
ATCC  American Type Cell Culture Collection 
ATP  Adenosine 5’-triphosphate 
av  Average 
B  Amount of total protein estimated by the method of Bradford 
bN/U  Y intercepts of the native and unfolded baselines 
bp  Base pair 
BSA  Bovine serum albumine 
c  Concentration 
CD  Circular dichroism 
CIAP  Calf intestinal AP 
CO2  Carbon dioxide 
CPP  Cell penetrating peptide 
d  Path lenght 
Da  Dalton 
DAPI  4’,6-Diamidino-2-phenylindole dihydrochloride 
DMEM  Dulbecco’s minimal essential medium 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
dNTP  Deoxynucleotide 
  Extinction coefficient 
EC50  Median effective concentration 
ECL  Enhanced chemiluminescence 
E. coli  Escherichia coli  
EDTA  Ethylenediaminetetraacetic acid 
ESI  Electrospray ionization 
EtBr  Ethidium bromide 
FBS  Fetal bovine serum 
Fc  Crystallizable fragment 
FITC  Fluorescein iso-thiocyanate 
Fmoc  N-(9-fluorenyl)methoxycarbonyl 
Fv  Variable fragment 
H  Enthalpy, hillslope 
HA  Hemaglutinin protein 
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HBV  Hepatitis B virus 
HPLC  High-performance liquid chromatography 
HPV  Human papillomavirus 
HRP  Horseradish peroxidase 
I  Input 
IPTG  Isopropyl -D-1-thiogalactopyranoside 
IUB  International union of biochemistry 
IUPAC  International union of pure and applied chemistry 
KA  Association constant 
KD  Dissociation constant 
kDa  Kilo Da 
L0  Initial concentration of the ligand 
lac  Lactose 
LB  Luria-Bertani 
M  Monomer, mol/L 
mA  Milliampere 
MALDI  Matrix-assisted-laser desorption/ionization 
MH+  Mass-to-charge ratio 
min  Minutes 
mN/U  Slopes of the baselines 
MPP  Membrane permeable peptide 
MR  Molecular mass 
mRNA  Messenger RNA 
MRW  Mean residue weight 
MS  Mass spectrometry 
MW  Molecular weight 
m/z  Mass-to-charge ratio 
N2  Nitrogen 
NA  Number of amino acids 
ND  Not determined 
Ni-NTA  Nickel-nitrilotriacetic acid 
NLS  Nuclear localization signal 
NMR  Nuclear magnetic resonance 
NP-40  Nonidet P-40 
obs  Observed 
OD  Optical density 
P0  Initial concentration of the protein 
PAGE  Polyacrylamide gel electrophoresis 
PBS  Phosphate-buffered saline 
PCR  Polymerase chain reaction 
PDB  Protein data bank 
PEG  Poly(ethylene glycol) 
PEO  Poly(ethylene oxide) 
PFA  Paraformaldehyde fixation 
PL  Concentration of the protein/ligand complex 
PNK  Polynucleotide kinase 
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PPAA  Poly(propyl-acrylic acid) 
PTD  Protein transduction domain 
PTD-SA  Transvidin 
PTD-ST  Transtactin 
R  Gas constant 
RE  Restriction endonucleases 
RIPA  Radioimmunoprecipitation assay 
RLB  Reporter lysis puffer 
RNA  Ribonucleic acid 
RNAi  RNA interference 
RP  Reversed phase 
rpm  Rounds per min 
RT  Room temperature 
SA  Streptavidin 
SDS  Sodium dodecyl sulfate 
siRNA  Small interfering RNA 
ST  Strep-Tactin 
SV  Simian virus 
T  Temperature, tetramer, transporter 
TAE  Tris-acetate-EDTA 
Tat  Trans-activator 
TE  Tris EDTA 
TEMED  Tetramethylendiamin 
TFA  Trifluoroacetic acid 
TLM  Translocation motif 
Tm  Melting temperature 
TMB  3,3’,5,5’-Tetramethylbenzidine 
TOF  Time-of-flight 
Tris  Tris(hydroxymethyl)-aminomethan 
TRITC  Tetramethyl rhodamine iso-thiocyanate 
U  Unit 
UV  Ultraviolet 
V  Volt 
Vis  Visible 
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